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 Colorectal cancer (CRC) is the third leading cancer in the United States with an 
estimated 132,700 new cases and 49,700 deaths in 2015. Well-performed screening 
colonoscopies prevent cancer by allowing visualization of the entire colon and removal of 
precancerous polyps (adenomas). Persons with high-risk polyps at screening are therefore 
advised to undergo periodic surveillance colonoscopy. Screening and surveillance 
colonoscopy guidelines were updated by the U.S. Multi-society Task Force (USMSTF) in 
2006, which emphasized risk stratification by polyp features at screening colonoscopy.  
      This is a retrospective cohort study of patients with screening colonoscopy at an 
endoscopy center in South Carolina between September 2001 and February 2010, 
followed through February 2011. The aims of the study are to: (a) assess the impact of 
the 2006 USMSTF guidelines on CRC surveillance and re-screening timing, and, (b) 
identify the predictors of guideline-concordant surveillance colonoscopy 
recommendations, overuse or underuse.  
       We compared patients with screening colonoscopy in the pre- and post-2006 periods 
for appropriate use (surveillance interval as per guideline), overuse (premature relative to 
guideline) and underuse (delayed or not done). We classified patients by cancer risk, and 
comparisons were made using chi-square tests, Kaplan-Meier (KM) approach with log-




      Of 16,897 study patients, 4,234 had adenomatous polyps (surveillance-eligible), of 
whom 2,195 (51.4%) had a surveillance colonoscopy, 91.8% with inappropriate 
surveillance timing. We observed underuse among ≤1-, and 3-year surveillance groups 
(p<0.001), and overuse among 5-year recommended surveillance (p<0.001). Among 
those without adenomas at initial colonoscopy, 14.3% (1,793 of 12,571 pre-period 
patients) had premature second colonoscopy after a mean of 4.65 years. In multivariate 
analysis, patients with large adenoma (≥ 10 mm) (OR: 1.81; 95%CI: 1.25-2.63), and ≥2 
advanced characteristics (OR: 2.26; 95%CI: 1.30-3.93), and post-guideline period (OR: 
1.73; 95%CI: 1.30-2.31) were associated with overuse. Delayed surveillance was more 
likely in patients with the largest adenoma found in the right colon (OR: 1.49; 95%CI: 
1.12-1.98) and Medicaid beneficiaries (OR: 3.22; 95%CI: 1.14-9.09). 
       Minimizing overuse among low-risk patients will spare provider time for high-risk 
patients and reduce colorectal cancer incidence at no extra cost.
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       This chapter describes background information on colorectal cancer (CRC) and 
significance of the study objectives. There are four sections: (1) background, (2) 
objectives, (3) significance of the study, and (4) limitations.  
1.1 Background       
         Colorectal cancer (CRC) is the third leading cancer in the United States with an 
estimated 132,700 new cases and 49,700 deaths in 2015(ACS, 2015). Incidence and 
mortality rates vary by gender, age, and race/ethnicity. There has been an annual 4.3% 
decline in CRC incidence among adults aged over 50, but there has been an increase of 
1.8% per year in the below 50-age group from 2007 to 2011(ACS, 2015). Younger CRC 
patients aged < 40 years typically have more advanced disease, estimated at more than 
one-tenth of CRC cases (Ahnen et al., 2014; Bailey et al., 2015). However, patients in 
this age group account for 6.5% of CRC-related deaths (Fairley, Li, Komar, Steigerwalt, 
& Erlich, 2014; Siegel, Desantis, & Jemal, 2014). 
     Adenomatous polyps are the most frequent neoplasm found during colorectal 
screening (Imperiale et al., 2000; Schoenfeld et al., 2005). At least ≥30% of men and 




are found to have ≥ 1 adenomas (Levine & Ahnen, 2006; Rex et al., 2015). Well-
performed screening colonoscopies prevent cancer by enabling visualization and removal 
of precancerous polyps (adenomas). Therefore, the presence of adenomas on the most 
recent colonoscopy can be an indicator for subsequently advanced adenomas (Imperiale 
et al., 2014; Laiyemo et al., 2009; Pinsky et al., 2009; Robertson et al., 2009). Screening 
colonoscopy can achieve 76-90% reduction in CRC incidence and mortality can be 
reduced by 53-89% after colonoscopic polypectomy (Winawer et al., 1993; Xirasagar et 
al., 2015; Zauber et al., 2012).  
        Persons with high-risk polyps at screening are advised to undergo periodic 
surveillance colonoscopy. Surveillance guidelines have been updated by the U.S. 
Multisociety Task Force (USMTF) Colorectal Cancer and the American Cancer Society 
(ACS) in 2006. Risk stratification is a strategy to markedly reduce the intensity of follow-
up evaluation in a substantial proportion of patients. The guidelines recommend the 
following surveillance intervals post baseline screening: 2-6 months for patients with 
sessile adenomas that are removed piecemeal; at 1 year for patients with hyperplastic 
polyposis syndrome or > 10 adenomas; at 3 years for patients with 3-10 adenomas, ≥ 1 
cm adenoma, or any adenoma with villous features, or high-grade dysplasia; at 5 years 
for patients with 1 or 2 small tubular adenomas or any adenoma without advanced 
features; and no surveillance (i.e., resume 10 year screening interval) for patients with 
small rectal hyperplastic polyps or normal tissues(Winawer et al., 2006).  
         However, many studies reported that time to re-examination varied in clinical 
practice (Kahn et al., 2015; Schoen et al., 2010; Sint Nicolaas et al., 2013). Many related 




procedure characteristics. A possible reason is that very few data sources are available 
that are validated to have achieved polyp clearance at surveillance. Most of surveillance 
studies focused on surveillance use among patients with polyps found at screening 
examination but not those with no polyps found. (Laiyemo et al., 2009; Morelli, 
Glowinski, Juluri, Johnson, & Imperiale, 2013; Pinsky et al., 2009; Robertson et al., 
2009) . Documenting timely surveillance and the rate of new polyp development may 
increase the efficiency of surveillance use while decreasing the subsequent risk of cancer 
for high-risk individuals (de Jonge et al., 2012; Winawer et al., 2006). Therefore, this 
study explores the relationship between timely surveillance colonoscopy and baseline 
findings on polyp, patient, and colonoscopy procedure characteristics. It uses secondary 
data from a endoscopy center which has a documented higher CRC prevention rate than 
any community-based series documented (Xirasagar et al., 2015). 
1.2 Objectives 
       The aims of the study are to: (a) assess the influence of a change in colorectal cancer 
surveillance guidelines and to characterize surveillance colonoscopy recommendations 
after initial screening among patients with a near-complete polyp clearance on 
colonoscopy at a community-based facility, and, (b) identify the predictors of guideline-
concordant surveillance colonoscopy recommendations, as well as those associated with 
overuse or underuse relative to guidelines.   
      Using surveillance recommendations and risk stratification to examine the factors in 
surveillance timing may enable identification of measures to optimize surveillance 
colonoscopy use at endoscopy centers in the United States. We tested our objectives, 




patient characteristics (patient age, gender, race, and insurance status), and guideline date 
(pre-2006 period, and 2006 and later). 
     The main study objectives are as follows:       
1. To study the timing of surveillance colonoscopy relative to the recommended 
intervals for patients with an initial colonoscopy in the pre-2006 period vs. 2006 
and later. 
2. To identify the factors driving the likelihood of guideline-concordant surveillance 
in a total cohort of patients with an initial colonoscopy.  
1.3 Significance of the study 
        The quality of baseline colonoscopy plays a major role in determining the 
appropriate postpolypectomy surveillance interval (S. J. Winawer et al., 2006). Therefore, 
without a good clearing of the colon at initial screening, patients are at increased risk for 
subsequently advanced neoplasms(Barclay, Vicari, Doughty, Johanson, & Greenlaw, 
2006). Following the surveillance guidelines can prevent the disease, and reduce the 
burdens on medical resources. A large number of patients with adenomas have been 
diagnosed as a result of the increased use of CRC screening, but adherence to 
surveillance guidelines remains low. Therefore, the management of surveillance 
colonoscopy appropriateness is very important.            
     This study aims to contribute the literature by: 
1. Using over 10 years of clinical data on colonoscopy with the near-complete polyp 
clearance and with nearly completed polyp information for analysis 
2. Profiling surveillance in a community-based setting, stratifying risk groups based 




3. Determining the influence of a change in the 2006 guidelines for surveillance 
colonoscopy on actual practice 
4. Identifying the predictors at initial colonoscopy that predict guideline-
concordance: adenoma features (number, size, location, or histology), patient 
characteristics (gender, age, race, and insurance status), and guideline date. 
1.4Limitations 
      There are some study limitations associated with the data characteristics and study 
design compared to other studies in the literature. 
1. The clinical dataset comes from a single endoscopy center in South Carolina. 
Therefore, the findings may not generalize to the US or other endoscopy centers. 
2. The retrospective study design entails some loss to follow-up because some patients 
may have chosen to undergo surveillance colonoscopy at other facilities. It also 
precludes understanding the extent to which selection bias affects the composition 
of the study cohort. 
3. In the case of multiple polyps within one clinical segment sent for pathology 
examination in a single jar, the pathology report may not have clearly identified the 
number of polyps with different histology features. 
4. The clinical dataset does not document information about a family history of CRC 
or comorbidities. Those factors are also important because they may contribute to 




CHAPTER 2  
LITERATURE REVIEW 
       This chapter includes 6 sections on colorectal cancer (CRC), including disease 
background, strategies for CRC prevention, surveillance guidelines, and management, 
colonoscopy quality indicators, patient characteristics affecting colonoscopy performance, 
and prediction of adenoma recurrence. Finally, the current research and gaps in research 
will be identified based on literature findings. 
 2.1 Colorectal cancer (CRC)  
        This section summarizes the background on CRC, including symptoms and risk 
factors, incidence and mortality, prevention methods, recommended prevention 
guidelines, utilization of CRC screenings, and barriers to CRC screenings. 
2.1.1. Definition of colorectal cancer (CRC)          
        Colorectal cancer is cancer affecting the colon or rectum, and can be referred to 
separately as colon or rectal cancer, depending on where it is located. Most colorectal 
cancers develop very slowly over several years. Before cancer develops, the growth of 
the tissue or tumor usually begins as a non-cancerous polyp in the inner surface of the 
colon and rectum that may change into cancer. Certain kinds of polyps, called 
adenomatous polyps or adenomas, occur in 30 to 50 % of adults and can be completely 




cancer (Levine & Ahnen, 2006).  At least 25% of men and 15% of women who undergo a 
colonoscopic screening by experienced endoscopists are found to have one or more 
adenomas (ACS, 2014; Winawer et al., 2006).  
         A polyp can be of two types: (1) non-adenomatous lesions (hyperplastic polyps) 
and (2) adenomatous lesions (lesions composed of tubular and/or villous structures 
showing intraepithelial neoplasia). Adenomas are classified as (1) non-advanced 
adenomas (small, tubular adenomas) and (2) advanced adenomas (10mm in diameter or 
larger, presence of high-grade dysplasia (including carcinoma-in-situ), or greater than 
25% villous or tubulovillous features). CRC is diagnosed when the invasion of malignant 
cells through the muscularis mucosa has taken place. Advanced colorectal neoplasia is 
defined as lesions that are either benign advanced adenomas or invasive cancer (ACS, 
2014; Martinez et al., 2009; Tholoor, Tsagkournis, Basford, & Bhandari, 2013; Winawer 
& Zauber, 2002).  
2.1.2. Incidence and mortality  
       CRC is the third leading cancer in both men and women in the United States, an 
estimated 132,700 new cases and 49,700 deaths are expected in 2015(ACS, 2015) . In 
South Carolina during 2015, an average of 2,130 adults is diagnosed and 840 adults die 
from CRC(Siegel, Miller, & Jemal, 2015). Incidence and mortality rates vary by gender, 
age, and race/ethnicity. From 2007 to 2011, there has been an annual 4.3% decline in 
CRC incidence among adults aged over 50. However, there has been a concurrent 1.8% 
annual increase in the below 50-age group, which is expected to amount to a 28-46% 
increase in this age group by 2030(ACS, 2015; Bailey et al., 2015). Younger CRC 




patients account for more than one-tenth of CRC cases (11% of colon cancers and 18% of 
rectal cancers)(Ahnen et al., 2014; Bailey et al., 2015). However, patients in this age 
group account for 6.5% of CRC-related deaths. By gender and race, CRC incidence and 
mortality rates among men are 30% and 40% higher than in women, and 25% and 50% 
higher among blacks than in whites(Siegel et al., 2014). 
2.1.3. Signs and symptoms 
       Screening is important to prevent the disease and detect CRC early because 
adenomas and early stage CRC have no symptoms. There are few than 10% of CRCs 
begin as polyps (Levine & Ahnen, 2006). Symptoms may include bleeding from the 
rectum, blood in the stool or in the toilet after having a bowel movement, having dark or 
black stools, a change in the shape of the stool, cramping pain in the lower stomach, a 
feeling of discomfort or urge for bowel movement when there is no need to have one, 
recent onset of constipation or diarrhea that lasts for more than a few days, and 
unexplained weight loss (ACS, 2015). 
2.1.4. Risk factors 
        A risk factor is defined as anything that affects the chances of developing CRC that 
may increase or decrease the likelihood of colorectal polyps or cancer. The risk of CRC 
increases with age: about 90% of cases are diagnosed in adults aged 50 or older (Siegel et 
al., 2014). Hereditary factors also play a role, including family history of CRC or 
adenomatous polyps. About 5% of CRCs are associated with well-defined inherited 
syndromes, such as Lynch syndrome and familial adenomatous polyposis (FAP) 
(Jasperson, Tuohy, Neklason, & Burt, 2010). These conditions cause cancer typically at a 




been affected by the disease without a defined inherited syndrome (Jasperson et al., 2010). 
Personal medical factors associated with increased cancer risk include a personal history 
of colorectal polyps or CRC, inflammatory bowel disease, or history of other cancers. 
Lifestyle-related factors also play an important role such as obesity, physical inactivity, 
smoking, dietary factors, and alcohol use(ACS, 2014).  
2.2 Colorectal cancer (CRC) prevention and screening 
recommendations 
         This section describes common CRC screening types and recommended guidelines 
for different risk groups, the rationale for screening guidelines, screening examinations 
that can find colorectal polyps and cancer, screening recommendations, and utilization 
and barriers of CRC screening. 
2.2.1. Background of CRC screening         
        Over several decades, CRC screening methods have improved significantly and can 
prevent cancer effectively. In the early years, the screening guidelines were reviewed and 
approved by the Practice Parameters Committee of the American College of 
Gastroenterology (ACG) and by the ACG Board of Trustees. It was also the first 
organization to recommend colonoscopy as the preferred screening tool to prevent CRC. 
In 2006, the guidelines were revised by a joint committee of the USMSTF and the ACS, 
and then again revised in 2008 in partnership with the American College of Radiology 
(Rex et al., 2009; Winawer et al., 2006).   
      The guidelines draw a distinction between screening tests that primarily detect cancer 
after it has developed (e.g., stool tests), and those that are more likely to detect both 




visualize the growths. These include the flexible sigmoidoscopy, colonoscopy, CT 
colonography, and double-contrast barium enema (Levin et al., 2008). The screening 
recommendations emphasize that cancer prevention should be a main goal of screening. 
Thus, regular colorectal cancer screening is one of the most powerful weapons for 
preventing CRC because it is a process of looking for pre-cancer in adults who have no 
symptoms, as well as in adults with symptoms of CRC and other digestive diseases.     
      Despite many options for CRC screening, the screening rates remained low. There are 
65% of US adults had CRC screening, which are lower than the target of 80% by 2018 
(CDC, 2013; Meester et al., 2015). Thus, the preferred strategy emphasizing the use of 
colonoscopy in CRC screening recommendation has been replaced by the “menu of 
options” approach (Rex et al., 2009). The U.S. Preventive Services Task Force (USPSTF) 
recommends routine screening from this “menu” including colonoscopy, flexible 
sigmoidoscopy, and fecal blood test (FOBT or FIT). It recommends 10-year for 
colonoscopy, 5-year for flexible sigmoidoscopy, and 1-year for FOBT or FIT (CDC, 
2013; USPSTF, 2008).       
2.2.2. Tests that can detect both colorectal polyps and cancer      
      There colorectal cancer screening can visualize the colon physically to find abnormal 
areas. It can be done with an endoscope inserted through the rectum or by special 
imaging (x-ray) tests. Polyps found can be removed by endoscopy before they become 
cancerous. Therefore, these tests are the preferred tools for polyps and cancer detection. 
Table 2.2.1 shows the comparative features and advantages/ disadvantages of the widely 






         A colonoscope is similar but more complex than a sigmoidoscope; it is, longer and 
can be used to examine the entire length of the colon and rectum than a sigmoidoscope. A 
high-quality of bowel preparation by thorough cleaning is required for the physician to 
view the colon clearly. It involves taking medication that causes diarrhea, and then to 
empty the colon. The medication is taken by mouth, and comes in liquid or tablet form 
(ASGE, 2016). Moreover, sedation is usually provided during the examination to 
minimize discomfort (Levin et al., 2008). If a polyp is found, it may be removed by 
passing a wire loop through the colonoscope either to cut the polyp from the wall of the 
colon (via hot or cold biopsy) or destroy it in place using an electric current (ACS, 2011). 
This may be done in a hospital outpatient department, clinic, or physician’s office (ACS, 
2014).  
       Since colonoscopy has the advantage of detecting polyps throughout the entire colon 
and rectum, it has become the most commonly recommended strategy to prevent the 
disease (Rex et al., 2009). Screening colonoscopy can reduce the incidence of CRC by 
67-83% and CRC mortality by 65-89% (Kahi, Imperiale, Juliar, & Rex, 2009; S. J. 
Winawer et al., 1993; Xirasagar et al., 2015; Zauber et al., 2012) . A reduction in the 
incidence of CRC is documented at 76-90%, with 53% reduction in mortality by 
colonoscopic polypectomy (Winawer et al., 1993; Zauber et al., 2012).        
(2) Flexible sigmoidoscopy 
        Flexible sigmoidoscopy is used to visualize part of the colon and rectum with a 
flexible sigmoidoscope. Using the sigmoidoscope, the doctor can view the inside of the 




Because this scope is only 60 cm long, the doctor can see the entire rectum but less than 
half of the colon. Simple bowel preparation is needed before the test and the procedure is 
typically performed without sedation. However, this test may be uncomfortable because 
of the air injected into the colon. If a pre-cancerous adenoma or colorectal cancer is found, 
the patient needs to be referred for a colonoscopy so that the entire colon can be 
examined (ACS, 2011, 2014).  
       This test can detect 17.3% of adenomas, achieves 33-45% CRC prevention and 
reduces CRC mortality by 43% (Atkin et al., 2010; Brenner, Chang-Claude, Seiler, 
Sturmer, & Hoffmeister, 2007; Holme et al., 2014). Cancer prevention is increased to 50-
55% when a sigmoidoscopy with abnormal findings is followed by a colonoscopy 
(Brenner et al., 2007).  
2.2.3. Tests that mainly find colorectal cancer         
      These types of test examine the stool for secondary signs of cancer such as bleeding 
or shedding of cells and are less invasive and easier to conduct. However, positive results 
on one of these screening tests will require an invasive test such as a colonoscopy to find 
the lesions (Table 2.2.1).  
      The fecal occult blood test (FOBT) is a widely-used test because it is approximately 
equally effective in life-years gained when done regularly annually, comparable to 
colonoscopy and sigmoidoscopy. Use of annual high-sensitivity FOBT (sensitivity for 
cancer 70%) has a false-positive rate less than 10% (specificity >90%) (USPSTF, 2008; 
Zauber et al., 2008). The idea behind this test is that blood vessels at the surface of larger 
colorectal polyps or cancers are often fragile and easily damaged by the passage of feces. 




rarely enough to be visible in the stool. In addition, the FOBT kit can be obtained from a 
health care provider for use at home. It is used to find occult blood which cannot be seen 
with the naked eye in feces, but which can be detected in the stool through a chemical 
reaction. Some foods or drugs may affect the test, so patients require a physician’s advice 
on diet and medication before the examination. If the test is positive, a colonoscopy will 
be needed to find the reason for the bleeding (ACS, 2014).  
      An annual FOBT can reduce CRC by 20% by detecting cancer or a polyp early, 
resulting in their subsequent removal by colonoscopy(Mandel et al., 2000). In terms of 
mortality, it reduces approximately 15% of CRC deaths (Hardcastle et al., 1996; 
Scholefield, Moss, Sufi, Mangham, & Hardcastle, 2002). See Table 2.1. 
2.2.4. Screening recommendations 
      The USPSTF and ACG have recommended CRC screening guidelines for different 
risk groups. For average-risk individuals, CRC screening should begin at age 50. 
Average-risk persons are those without a family history of colorectal neoplasia, except 
average risk African Americans (AAs) who should begin screening at age 45 (Rex et al., 
2009; USPSTF, 2008) . However, adults after 75 years of age do not need to take routine 
screening because the potential benefits of screening may be outweighed by the harms 
and other competing causes of mortality (USPSTF, 2008). Regarding test characteristics, 
the different CRC tests have different time intervals for follow-up screenings: 
colonoscopy every 10 years, sigmoidoscopy every 5 years, and FOBT (or FIT) every year. 
       Conversely, high-risk groups should have intensive screening. High-risk groups are 
those with a family history of multiple relatives affected by CRC, FAP, and Hereditary 




CRC or advanced adenoma (adenoma ≥1cm in size, or with high-grade dysplasia or 
villous elements) diagnosed after 60 years of age should have a colonoscopy every 10 
years beginning at age 50 years. For those with relatives diagnosed before 60 years of age 
or having multiple first-degree relatives with CRC or advanced adenomas should have a 
colonoscopy every 5 years beginning at age 40, or 10 years younger than the age at which 
the youngest affected relative was diagnosed (Rex et al., 2009).  
2.2.5. Utilization and barriers of CRC screening 
         The prevalence of CRC screening in the general population has been steadily 
increasing since 2000. In the United States, the CRC screening rate increased 15.5% 
between 2005 and 2013 (Smith et al., 2015). The percent of the population that is up-to-
date with CRC screening has also increased from 42.5% in 2000 to 58% in 2010(T. F. 
Imperiale et al., 2014; Seeff et al., 2004; J.A. Shapiro et al., 2012; J.A.  Shapiro et al., 
2008). Another population-based survey identified 65% of US adults had CRC screening 
within the recommended time in 2012 (CDC, 2013). 
       Despite rising CRC screening rates, screening completion rates are still significantly 
lower than the target of 80% by 2018 set by the National Colorectal Cancer Screening 
Roundtable (Meester et al., 2015). Well-established barriers to colorectal cancer 
screening include lack of health insurance, low education levels, low income, without 
routine doctor's visits, and inadequate communication between physicians and patients 
(CDC, 2013; Doubeni, Laiyemo, Klabunde, et al., 2010; Doubeni, Laiyemo, Young, et al., 
2010; Ioannou, Chapko, & Dominitz, 2003; Klabunde et al., 2011; Seeff et al., 2004; 






Table 2.1 Advantages and disadvantages of the widely used screening methods: flexible sigmoidoscopy, colonoscopy, and FOBT 








 Fairly quick 
 Few complications 
 Minimal bowel preparation 
 Minimal discomfort 
 Sedation or a specialist needed 
 Views only 1/3 colon 
 Cannot remove large polyps 
 Small risk of infection or 
bowel tear 
 Colonoscopy necessary if 
positive findings 
5 years 33-45% 
Colonoscopy  Examine entire colon 
 Can biopsy and remove polyps 
 Can diagnose another disease 
 Required for positive findings 
by all other tests 
 Highly sensitive 
 Less frequent interval 
 May miss some polyps or 
cancer 
 Full bowel preparation needed 
 Expensive 
 Bowel tears or bleeding 




FOBT   No bowel preparation  
 Sampling is done at home 
 Low cost 
 Noninvasive 
 Multiple stool samples needed 
 Miss most polyps and some 
cancers 
 Have false-positives results 




Abbreviations: FOBT, fecal occult blood test. 
*




2.3 Surveillance management and rationale for the recommendations 
 This section describes the purpose of surveillance screening, the role of adenomatous 
polyps in surveillance management, and some evidence related to the rationale of the 
guidelines and predictors for surveillance behaviors. 
2.3.1. Purpose of surveillance management 
          Patients who’ve had a CRC removed are at risk for recurrent cancer and 
metachronous neoplasms in the colon, which are the main reasons that surveillance is 
needed.  However, many patients with low-risk adenomas found at initial colonoscopy 
are more likely to have early surveillance colonoscopy (Schoen et al., 2010; Sint Nicolaas 
et al., 2013). This places a huge burden on medical resources applied to surveillance. The 
efficiency of surveillance colonoscopy can decrease the cost and risk of resources for 
unnecessary examinations. Thus, USMSTF and ACS updated joint guidelines on 
postpolypectomy and postcolorectal cancer resection surveillance in 2006, trying to shift 
some available resources from surveillance purposes to screening (Rex et al., 2006;  
Winawer et al., 2006). 
       There are two fundamental goals of surveillance of patients with cancer or a history 
of polyps. One goal is the detection of early recurrences of the initial primary cancer at an 
early stage, and another is the detection of metachronous colorectal neoplasms. The most 
important purpose is to resect synchronous adenomas missed during the initial 
colonoscopy (Bond, 2000; Rex et al., 2006). However, it is not always beneficial to those 
patients when they have a colonoscopy annually because of the huge burden on medical 




colonoscopies on the health care system becomes substantial and should be well 
established. 
2.3.2. Roles of adenomas and serrated lesions 
      There are two major classes of lesions: polyps and serrated classes of colorectal 
adenomas. The best-known class is adenomatous polyps (adenomas). It may be 
characterized pathologically as high or low-grade dysplasia, tubular, or villous. 
Adenomas with those features are widely understood to be premalignant lesions, 
particularly at risk for increasing in size, acquiring high-grade dysplasia features, or 
villous elements (Vogelstein et al., 1988). Another class of colorectal lesions is distinct 
from adenomas, called serrated lesions. It includes 3 major subtypes termed as (1) 
hyperplastic polyp (HP), (2) sessile serrated adenoma/polyp (SSA/SSP), and (3) 
traditional serrated adenoma (TSA) (Snover, Ahnen, & Burt, 2010). Only HPs of serrated 
classes have the potential for malignancy.         
      Because all adenomas are dysplastic in contrast to serrated lesions, which are 
generally non-dysplastic, adenoma detection rates (ADRs) have become the most 
important quality indicators in colonoscopy performance (Hewett, Kahi, & DK., 2010; 
Hewett & Rex, 2010; Rex et al., 2015). Adenomatous polyps are the most common 
neoplastic findings in adults who have a colorectal screening or diagnosed symptoms, the 
characteristics of which can be a marker to determine risk level (Lieberman et al., 2012; 
Rex et al., 2006; Winawer et al., 2006). These adults still have a lifelong risk of 
subsequent adenomas and colorectal cancers despite adequate polypectomy (Blumberg, 
Opelka, Hicks, Timmcke, & Beck, 2000; Marae & Williams, 1982; Waye & Braunfeld, 




the standard of care for those patients, particularly for these with advanced adenomas 
(Blumberg et al., 2000; Levine & Ahnen, 2006; Lieberman et al., 2007).  
       The presence of low- or high- risk adenomas determines the recommended 
surveillance interval. The presence of an advanced adenoma is adopted as an outcome 
measure requiring early surveillance tests because there are more associations with 
cancer development. Advanced adenomas can be a surrogate biological indicator of 
cancer risk (Winawer et al., 2006; Winawer et al., 1993; Zauber et al., 2012). However, 
the true rate of polyp recurrence is unknown since polyps detected during follow-up 
examinations may be cumulative (missed at the previous examination), or could be new 
polyp growth. The estimated miss rate for HPs is 31% versus 20% for adenomas, while 
miss rates for serrated lesions may be higher than for adenomas (Heresbach et al., 2008). 
Missed lesions may also have occurred among patients with interval CRCs (86%) (le 
Clercq et al., 2014).  Despite missed adenomas leading to cancer, adults with serrated 
lesions or an advanced adenoma are shown to have a higher risk of neoplasia at follow-up 












2.3.3 .Surveillance methods and recommendation       
          A colonoscopy is a common tool for surveillance of previously developed polyps 
or cancers: about 24% of all colonoscopy patients and 22% of patients aged ≥ 50 years 
had a colonoscopy for surveillance purpose (Lieberman, De Garmo, Fleischer, Eisen, & 
Helfand, 2000; Lieberman, Holub, Eisen, Kraemer, & Morris, 2005). In the 1970s to 
early 1990s, physicians commonly recommended annual follow-up colonoscopies 
following all polypectomies despite there were no guidelines providing guidance on this 
issue (Rex et al., 2006). In order to reduce resource utilization and improve the efficiency 
of examination, the guidelines are continuously updated by new evidence. The results of 
the National Polyp Study in 1993 led to the recommendation that the first 
postpolypectomy examination should be done 3 years after polypectomy for most 
patients with large (>10mm) or multiple adenoma, published by a gastrointestinal 
consortium in 1997. In 2003 and 2006 the guidelines were updated, and colonoscopy is 
now the only follow-up examination recommended because it is the most effective tool to 
prevent disease (Winawer et al., 2003; Winawer et al., 2006). The 2006 guidelines are 
shown in Table 2.2. 
        Since 2006, researchers have focused on the histology and number of polyps 
detected, the risk of interval CRC, CRC found in the proximal colon, and the role of 
serrated polyps (Lieberman et al., 2012; Winawer et al., 2006). In 2012, the 2006 
guidelines were reaffirmed based on stronger evidence and refined features based on risk 
stratification principles. Specifically, the researchers updated their recommendations for 
follow-up exams following a finding of no polyp, 1-2 small tubular adenomas, 3-10 




adenomas at baseline examination (Lieberman et al., 2012). An update of the 2012 
USPSTF and ACS surveillance guidelines is currently under progress.  
      Individuals are recommended a 10-year follow-up colonoscopy if they have small 
rectal hyperplastic polyps or hyperplastic polyps without advanced features, considered 
normal. A 5 to 10-year follow-up is recommended when they have only 1 or 2 small (< 
1cm) tubular adenomas with only low-grade dysplasia. A 3-year follow-up is 
recommended when they have 3 to 10 adenomas, any adenoma ≥ 1 cm, any adenoma 
with villous features or high-grade dysplasia, any sessile serrated polyp ≥ 1 cm, any size 
of the sessile serrated polyp with high-grade dysplasia, or a traditional serrated adenoma 
(TSA). The TSA are a type of colorectal polyp with neoplastic potential. It is a rare lesion 
located primarily in the left colon and rectum, and the only member of the serrated class 
that is uniformly dysplastic (Chetty, Hafezi-Bakhtiari, Serra, Colling, & Wang, 2015). If 
the follow-up colonoscopy is normal or shows only 1-2 small tubular adenomas with 
low-grade dysplasia, then the interval should be 5 years. The shorter (<3 years) interval is 
recommended when they have > 10 adenomas at the screening examination. A 2 to 6-
month follow-up is recommended if they had sessile adenomas removed piecemeal. 
People with serrated polyposis syndrome should have surveillance colonoscopy at a 1-
year interval. The intensive surveillance  is indicated when the family history may 
indicate HNPCC, which is recommended every 2 years follow-up beginning at age 20-25 
years until age 40 years, and then annually (Lieberman et al., 2012; Winawer et al., 2003; 
Winawer et al., 2006).  The time intervals of surveillance colonoscopy by index polyp 





2.3.4 .Adherence to surveillance screening  
         The importance of optimal surveillance colonoscopy consistent with 
recommendations is to achieve higher ADRs in contrast to over-utilization of procedures 
(Sint Nicolaas et al., 2013). Although recent evidence supports that colonoscopic 
polypectomy reduces subsequent colorectal cancer incidence, adherence to surveillance 
guidelines is variable with reports of overutilization in the low-risk groups and 
underutilization in high-risk groups. Over 50% of early surveillance colonoscopies were 
conducted for low-risk populations (Mysliwiec, Brown, Klabunde, & Ransohoff, 2004). 
Another clinical trial followed participants for 5 years and demonstrated overuse of 
surveillance among low-risk adults and underuse among high-risk adults. For example, 
approximately 70-80% of low-risk adults underwent surveillance screening at 3-4 years 
(Schoen et al., 2010). Medicare beneficiaries who underwent colonoscopy with 
polypectomy (<50% received surveillance) also reported underuse of follow-up 
colonoscopy at 5 years, but >30% of the follow-up colonoscopies were overused in adults 
without any polyp (Cooper, Kou, Barnholtz Sloan, Koroukian, & Schluchter, 2013).  
       Other studies from other countries reported consistent findings: around 20-30% of 
surveillance colonoscopies were consistent with the guidelines (Schreuders et al., 2013; 
van Heijningen et al., 2015). However, Menees et al and Kahn et al reported ≥ 75 % 
higher adherence to surveillance recommendations (Kahn et al., 2015; Menees, Elliott, 
Govani, Anastassiades, & Schoenfeld, 2014). 
        These findings can provide directions for closer surveillance colonoscopies after 
initial examination among high-risk individuals, and longer periods between follow-ups 




potential missed adenomas found in the proximal colon, more frequent follow-up 
examinations may helpful (Nakao, Fassler, Sucandy, Kim, & Zebley, 2013).  
2.3.5. Factors are associated with surveillance behaviors 
         Several demographic characteristics such as race, age, and smoking behavior, are 
associated with behaviors using surveillance colonoscopy. Black or other race, older age 
groups (65-plus years), and past or current smokers were less likely to have repeat 
examinations (Rolnick et al., 2005; Weissfeld et al., 2002). Of patients with screening 
colonoscopy who had Medicare coverage, about 42.5% had early repeat examinations. 
Black adults who had their procedures performed by surgeons or experienced 
colonoscopists also underwent early examinations (Goodwin, Singh, Reddy, Riall, & Kuo, 
2011). However, Kahn et al reported different findings: patients aged >65 years or with 
incomplete polyp resection had higher guideline-concordant surveillance(Kahn et al., 
2015). A possible explanation for this behavior is a lack of knowledge of guidelines by 
providers: around 76% of physicians are documented to disagree or ignore guidelines 
(Kruse, Khan, Zaslavsky, Ayanian, & Sequist, 2015; S. D. Saini, Nayak, Kuhn, & 


















Table 2.2 2006 U.S. Multi-Society Task Force guidelines for surveillance colonoscopy
*
  
Colorectal neoplasm characteristics and surveillance recommendations  
Patients with small rectal hyperplastic polyps should be considered to have normal 
colonoscopies, and therefore the interval before the subsequent colonoscopy should be 10 
years; an exception is patients with a hyperplastic polyposis syndrome
**
; they are at 
increased risk for adenomas and colorectal cancer and need to be identified for more 
intensive follow-up evaluation 
Patients with only 1 or 2 small (<1 cm) tubular adenomas with only low-grade dysplasia 
should have their next follow-up colonoscopy in 5–10 years; the precise timing within 
this interval should be based on other clinical factors (such as prior colonoscopy findings, 
family history, and the preferences of the patient and judgment of the physician) 
Patients with 3 to 10 adenomas, or any adenoma <1 cm, or any adenoma with villous 
features, or high-grade dysplasia should have their next follow-up colonoscopy in 3 years 
providing that piecemeal removal has not been performed and the adenoma(s) are 
removed completely; if the follow-up colonoscopy is normal or shows only 1 or 2 small 
tubular adenomas with low-grade dysplasia, then the interval for the subsequent 
examination should be 5 years 
Patients who have more than 10 adenomas at 1 examination should be examined at a 
shorter (<3 y) interval, established by clinical judgment, and the clinician should consider 
the possibility of an underlying familial syndrome 
Patients with sessile adenomas that are removed piecemeal should be considered for 
follow-up evaluation at short intervals (2–6 mo) to verify complete removal; once 
complete removal has been established, subsequent surveillance needs to be 
individualized based on the endoscopist’s judgment; completeness of removal should be 
based on both endoscopic and pathologic assessments 
More intensive surveillance is indicated when the family history may indicate HNPCC 
*
Reference: Winawer et al (2006). Guidelines for colonoscopy surveillance after 
polypectomy: a consensus update by the U.S. Multi-Society Task Force on Colorectal 
Cancer and the American Cancer Society. CA Cancer J Clin. 2006;56(3):143-59. 
**
Hyperplastic polyposis was defined by Burt and Jass for the World Health Organization 
International Classification of Tumors as: (1) at least 5 histologically diagnosed 
hyperplastic polyps proximal to the sigmoid colon, of which 2 are greater than 1cm in 
diameter, or (2) any number of hyperplastic polyps occurring proximal to the sigmoid 
colon in an individual who has a first-degree relative with hyperplastic polyposis, or (3) 
more than 30 hyperplastic polyps of any size distributed throughout the colon. Studies 














Table 2.3 Up-to-date guidelines for surveillance colonoscopy, 2012 guidelines  
Colorectal neoplasm characteristics Time interval (years) 
Hyperplastic polyps (no adenomas) 
Small (< 10 mm) rectal or sigmoid hyperplastic polyps 
10 
1 or 2 tubular adenomas ( < 1 cm) 5-10 
Small SSP (<10 mm) without dysplasia 5 
 ≥3 adenomas 
Any adenoma  ≥10 mm 
Any adenoma with villous features 
High-grade dysplasia 
SSP≥10 mm 
SSP with dysplasia 
TSA 
3 




Abbreviations: SSP, Sessile serrated polyp; TSA, Traditional serrated adenoma. 
*
Based on the World Health Organization definition of serrated polyposis syndrome, with 
one of criteria: (1) at least 5 serrated polyps proximal to sigmoid, with 2 or more ≥ 10 
mm; (2) any serrated polyp proximal to sigmoid with family history of serrated polyposis 































High-risk findings Low-risk findings 
3 years 
Adenoma, 5-10 years 
Serrated, 5years 
 
1st surveillance 1st surveillance 
High-risk  Low-risk  No adenoma  
3 years  5 years  5 years  
High-risk  Low-risk  No adenoma  
3 years  5 years  10 years  
Figure 2.1 Time intervals to surveillance colonoscopy by polyp status at index colonoscopy. 
*
High-risk findings are defined 
as ≥3 adenomas, any adenoma ≥10 mm, any adenoma with villous features, high-grade dysplasia, SSP≥10 mm, SSP with 
dysplasia, or TSA. Low-risk findings are defined as hyperplastic polyps, small (< 10 mm) rectal or sigmoid hyperplastic 





 2.4 Quality indicators of colonoscopy and patient characteristics 
associated with colonoscopy findings 
This section describes evaluation methods for improving the quality of colonoscopies. 
Many indicators are documented to measure the CRC screening performance, including 
interval CRC rates, serrated polyp detection rates, adenomatous polyps (adenoma 
detection rates), procedure indicators, endoscopist factors, and patient characteristics. 
2.4.1. Quality of colonoscopy 
Colonoscopy is the most effective screening tool to prevent CRC because it allows 
colonoscopic removal of polyps (Rex et al., 2009). However, the effectiveness of 
surveillance colonoscopy intervals assumes that high-quality examination was performed 
at screening and later colonoscopy. Failure of colonoscopy to consistently detect existing 
adenomas or other precursors of CRC is threatening the effectiveness of colonoscopy for 
the prevention of CRC. Good quality of colonoscopy with near-complete can prevent > 
80% of early and advanced CRCs for detection of early CRCs (Xirasagar et al., 2015).    
The American Society for Gastrointestinal Endoscopy (ASGE) and American College 
of Gastroenterology (ACG) published measures for reporting endoscopic performance in 
2006 (Rex et al., 2009), including pre-procedure, intra-procedure, and post-procedure 
measures. Pre-procedure represents nontechnical aspects of colonoscopy, such as the use 
of recommended surveillance intervals. Intra-procedure focuses on technical aspects of 
colonoscopy, such as bowel preparation, cecal intubation rate, adenoma detection and 
histology, and the provider’s experience (Lee, Levin, & Corley, 2013). Colonoscopic 
complications post-procedure are also measured for quality purposes (Hewett et al., 2010; 




 Overall, the adenoma detection rate (ADR) is always the priority indicator to 
measure colonoscopy performance. Consideration of other indicators together is needed 
for detecting subsequent adenomas because each indicator may be associated with others. 
Although patient characteristics do not directly affect the quality of performance, it may 
be necessary to adjust for them to account for patient mix complexity.     
2.4.2. Interval CRC  
        Interval CRC is defined as CRC diagnosed in the time interval between an initial 
and surveillance colonoscopy (Fayad & Kahi, 2014). After the first colonoscopy, patients 
with adenomas receive follow-ups with surveillance guidelines to identify and remove 
subsequent adenomas before they develop into cancer. However, colonoscopy is not 
always perfect, and thus interval cancers might be diagnosed between surveillance 
colonoscopies (Leung et al., 2010). Approximately 54- 79% of CRC patients had 
potential CRC at the screening or surveillance colonoscopy. The reason might relate to 
incomplete removal or missed cancer at prior examinations (Pabby et al., 2005; 
Robertson et al., 2005).  About 78% of person with a history of an advanced adenoma 
also had a higher risk of developing cancer (Leung et al., 2010). Therefore, interval 
check-ups may potentially prevent cancer by improving the baseline quality of 
colonoscopy and can be considered a “silver standard” for performance measurement 
(Fayad & Kahi, 2014).   
2.4.3. Serrated polyps 
       Non-neoplastic polyps have no malignant potential, including hyperplastic polyps 
(HPs) and inflammatory polyps. However, recent studies identified serrated polyps which 




have malignant potential. By histologic features, it can be classified as HPs, traditional 
serrated adenomas (TSAs), or sessile serrated adenomas (SSAs). These polyps are 
difficult to detect at endoscopy because they show the same color as the surrounding 
colonic mucosa may not be elevated and also may have a layer of adherent mucus which 
obscures the vascular pattern. It may need to be resected by colonoscopy several times 
(Bond, 2000; Kahi, 2015; Rex et al., 2012). Patients with serrated polyps had a 30% 
higher risk of developing CRC (Boparai et al., 2011; Chow et al., 2006). Particularly, the 
large serrated polyps (≥ 10 mm) are associated with advanced neoplasia with an 
estimated a 3-fold risk to be diagnosed with cancer (relative to patients without large 
serrated polyps) (Hiraoka et al., 2010; Holme et al., 2014).   
2.4.4. Adenomatous polyps (adenomas)         
     Those polyps are classified as neoplastic with malignant potential. Most colorectal 
cancers arise from neoplastic adenomatous polyps (adenomas). The adenoma detection 
rate (ADR) is the main indicator to measure the effectiveness of screening and 
surveillance colonoscopies as mentioned previously. ADR is defined as the proportion of 
screening colonoscopies with at least one adenoma found, and is the prime metric for 
quality measurement (Fayad & Kahi, 2014). Patient status at initial examination predicts 
adenoma recurrence, particularly advanced adenomas influence. Adenoma features are 
also used to stratify the risk. Risk features are multiple adenomas, large adenoma (≥ 1cm), 
adenoma in the proximal colon, high-grade dysplasia, tubulovillous adenomas, and 
villous adenomas. The literature on advanced adenoma and any adenoma findings at 
surveillance examinations as related to baseline findings are summarized in Table 2.4 and 




 (1) Number of adenomas 
         Adults with multiple adenomas had a higher risk of developing advanced adenomas, 
accounting for 2-4 fold higher risk among adults with at least 2 adenomas (compared to 
no adenoma). The risk of advanced adenomas found increased with increasing adenoma 
numbers (Bertario et al., 2003; Fairley et al., 2014; Martinez et al., 2009; van Heijningen 
et al., 2013). A meta-analysis identified adults with ≥ 3 adenomas as more likely to have 
advanced adenomas at follow-up examinations (RR: 2.52; 95% CI: 1.07-5.97) (Saini, 
Kim, & Schoenfeld, 2006). Chinese and Korean studies reported an adjusted hazard ratio 
(HR) of 2-3 with statistical significance among such adults (Chung et al., 2011; Huang et 
al., 2010).  
         Adenoma (any type) recurrence was reported among adults with ≥ 3 adenomas at 
baseline, an adjusted OR of 1.4 -2.4 showing statistical significance (Miller, Mukherjee, 
Tian, & Nagar, 2010; van Stolk, Beck, Baron, Haile, & Summers, 1998; S. J. Winawer et 
al., 1993), as also reported by Korea and Japan studies (Ji et al., 2009; Taniguchi et al., 
2014).  
(2) Size of adenoma 
        Adults with large adenoma (≥1 cm) were more likely to develop advanced adenomas 
at their next examination, with 2-4 fold higher risk of advanced adenoma recurrence 
(Bertario et al., 2003; Fairley et al., 2014; Laiyemo et al., 2008; Laiyemo et al., 2009; 
Martínez et al., 2001; Noshirwani, van Stolk, Rybicki, & Beck, 2000; Taniguchi et al., 
2014). A meta-analysis identified a pooled relative risk (RR) of 1.39 with statistical 
significance (Saini et al., 2006). A study from Korea reported similar findings, a 3-fold 




      Having a large adenoma at initial examination was also associated with any adenoma 
recurrence. About 60% of adults with any adenoma >1 cm had developed an adenoma at 
follow-up (Winawer et al., 1993). 
(3) Location of adenoma 
         Advanced adenoma at follow-up was more likely to happen with adenomas in the 
proximal colon at initial examination. About 58-65% of adults with proximal adenomas 
had a higher risk of having an advanced adenoma at follow-up examination (Laiyemo et 
al., 2008; Martinez et al., 2009; Martínez et al., 2001; van Heijningen et al., 2013). 
Overall, those with adenomas in the proximal colon had higher risks of developing any 
adenoma at surveillance, with 12.4-fold higher risk than those with adenomas in the distal 
colon (Miller et al., 2010). These findings were echoed by a Japanese study (Taniguchi et 
al., 2014). 
(4) Histology of adenoma  
          Histology is a particularly difficult predictor to evaluate because of different 
growth patterns of cancer cells and should be identified by the pathologist. Adenomas are 
classified as tubular (TA), tubulovillous (TVA), and villous adenomas, with about 4.8%, 
19%, and 38.4, respectively, showing malignant transformation (Bond, 2000; O'Brien et 
al., 1990). Patients with TVA or villous adenomas were more likely to develop advanced 
adenomas at surveillance examination, an adjusted RR of 1.26 - 2.43 (Laiyemo et al., 
2008; Saini et al., 2006). Lieberman et al reported much higher risks among adults with 
villous adenomas (RR=6.05), compared to no adenomas neoplasia (Lieberman et al., 
2007), and others reported 1.3-1.8 higher risk with TVA or villous adenomas at baseline 




adjusted HR of 2.57 (Huang et al., 2010). The risk of any adenoma recurrence was 2-fold 
among those with TVA compared to TA in another study (OR: 2.12; 95% CI: 1.12-4.02) 
(van Stolk et al., 1998).    
      Another pre-cancerous status is dysplasia in the colon or rectum mucosa with cells 
showing abnormal features. By definition, all adenomas have some levels of dysplasia 
(ACS, 2014; S. Winawer et al., 2003). Patients with high-grade dysplasia (HGD) were 
significantly more likely to develop advanced adenomas at surveillance, with an adjusted 
RR of 2-fold (Laiyemo et al., 2008; Saini et al., 2006). Martinez et al pooled data from 8 
prospective studies and reported 5% developing advanced lesions (Martinez et al., 2009), 
similar to Huang et al 2010. Another study reported much higher risk among those adults 
with HGD in a randomized controlled trial, with 6.89 relative risks of advanced 
adenomas, compared to adults without any neoplasia at baseline. The key difference is 
that this study used “no neoplasia” as the reference group, in contrast to other studies 
(Lieberman et al., 2007).     
       Overall, advanced adenoma at baseline examination is associated with a standardized 
incidence rate (SIR) of 2.23 (95%CI: 1.67-2.92) for subsequent advanced lesions and 
higher hazard ratio (HR: 5.95; 95%CI: 3.66-9.68) (Chung et al., 2011; Cottet et al., 2012).        
2.4.4. Procedure factors 
        Recently, the role of quality of initial colonoscopy in procedure-related factors has 
been studied. These features include bowel preparation status at initial colonoscopy and 






 (1) Bowel preparation status 
       Bowel preparation is a process before colonoscopy to obtain a clean bowel, allowing 
for examination of the whole mucosal surface. Inadequate cleansing can result in missed 
lesions and increased risk for subsequent adenomas. Thus, there is a strong relationship 
between detection of any significant lesions and bowel preparation quality (Froehlich, 
Wietlisbach, Gonvers, Burnand, & Vader, 2005; Harewood, Sharma, & de Garmo, 2003; 
Parra-Blanco et al., 2006).  
      Preparation adequacy can increase the detection of the colonic lesion by 21% (OR: 
1.21; 95%CI: 1.16-1.25) (Harewood et al., 2003). Froehlich et al reported lesion detection 
rates by the quality of preparation. About 47% and 81% were patients with high-quality 
preparation and intermediate-quality cleansing had detectable lesions than those with 
poor cleansing (Froehlich et al., 2005). A recent community-based study also reported 
that good bowel preparation was associated with adenoma detection (30%), compared to 
insufficient cleaning (OR: 3.4; 95%CI: 1.6-7.4) (van Heijningen et al., 2013).  
 (2) Cecal intubation status 
       Cecal intubation is defined to be achieved if the tip of the colonoscope is advanced to 
a point proximal to the ileocecal valve so that the entire cecum is visualized. Incomplete 
cecal intubation status may result in missed adenomas or cancer. It is an important quality 
metric and relatively easy to measure, and can be a marker of a complete colonoscopy 
(Fayad & Kahi, 2014; Rex et al., 2015). Skilled colonoscopists should be able to apply 
techniques to overcome the difficulties in most instances and reach the cecum in ≥ 90% 




      Reaching the cecum is lower for providers with low procedure volumes. Volumes of 
less than 500 in the previous year were associated with suboptimal rates of cecal 
intubation (OR range, 0.68-0.82) (Radaelli, Meucci, Sgroi, Minoli, & Italian Association 
of Hospital, 2008). It is also reported for procedures performed by non-
gastroenterologists, about 60-70% of patients whose procedures performed by surgeons 
and internists did not achieve intubation (OR, 0.3 and 0.4, respectively) (de Jonge et al., 
2012). Although cecal intubation is an important indicator of a complete colonoscopy, it 
is a process indicator of quality performance but not suggest determining high-quality 
colonoscopy. 
2.4.5. Endoscopist factors 
      Recently, there is increased awareness that the success of colonoscopy in preventing 
CRC is dependent on the skill and competence of the endoscopists to detect adenoma, 
currently a surrogate marker for quality (Lee et al., 2013). Studies from the US reported 
their endoscopists’ procedure volumes are associated with polyp detection and removal. 
About 10% of providers with the middle 50% of annual procedure volume were more 
likely to detect and remove polyps (Ko, Dominitz, Green, Kreuter, & Baldwin, 2010). 
Physicians performing > 100 colonoscopies per year also had a higher polyp detection 
rate (OR: 1.22; 95%CI: 1.04-1.43) in the UK (Bhangu et al., 2012).   
       Another driver of polyp detection and removal is the involvement of non-specialist 
endoscopists. The approximate rate of polyp detection and removal ranged from 7-25% 
when procedures are performed by non-gastroenterologists (Ko et al., 2010), rates that 
are validated by studies from other countries. A Canadian study reported that only 27-




0.73) (Jiang, Sewitch, Barkun, Joseph, & Hilsden, 2013). Higher polyp detection rates 
were reported for procedures by surgeons (OR: 1.15; 95%CI: 1.05-1.27) in the UK 
compared to non-gastroenterologists (Bhangu et al., 2012). Procedure performance by 
different specialty endoscopists is also associated with CRC detection. This is a 2-3-fold 
risk of missing polyps when procedures are performed by internists, general practitioners, 
or family physicians (Singh, Nugent, Mahmud, Demers, & Bernstein, 2010), and 
approximately 30-90% of missed CRC cases when performed by non-gastroenterologists 
(Baxter et al., 2011; Rabeneck, Paszat, & Saskin, 2010).    
       These studies confirm differences between specialists in polyp detection rates and 
removal, and therefore, the effectiveness to prevent early CRC. This may be due to 
differences in training because gastroenterologists generally receive the most intensive 
training in colonoscopy of all specialists. However, training in colonoscopy for primary 
care specialties is not required (American Association for the Study of Liver, American 
College of, American Gastroenterological Association, & American Society for 
Gastrointestinal, 2007)(Table 2.6).  
      Although colonoscopy screening performed by gastroenterologists shows higher 
adenoma detection rates, questions arise about whether crescent workloads are too high 
and may cause long waiting times for patients, particularly due to increasing caseloads 
for surveillance colonoscopy. Recent literature suggests shifting the workload to 
practitioners others than gastroenterologists, or involving assistants in procedures to 
increase the effectiveness of colonoscopy. Involving assistants may increase ADRs, 
accounting for 25-63% higher detection rates than without an assistant (23-59%), 




Dellon, Lippmann, Sandler, & Shaheen, 2008; Peters, Hasan, Jacobson, & Austin, 2010; 
Rogart, Siddiqui, Jamidar, & Aslanian, 2008; Xirasagar, Hurley, Sros, & Hebert, 2010). 
Other innovative approaches are also documented such as involving primary care 
physicians (PCPs), polyps search and removal during both scope insertion and 
withdrawal, and ensuring rescue assistance by experts if there is a difficulty during the 
procedure (Xirasagar et al., 2010).    
        In order to improve access to CRC prevention, shifting workloads to PCPs may be 
helpful because they are shown to perform consistent quality of CRC screening when 
they have the same training, about ≥25% ADR (46% among males and 30% among 
females) (Kolber, Wong, Fedorak, Rowe, & on behalf of the, 2013; Wilkins et al., 2009). 
Those findings are consistent with the USMSTF benchmark target average-risk 
individuals, an ADR of ≥25%, ≥30% among average-risk males and ≥20% among 
females (Rex et al., 2015). 
2.4.6. Patient characteristics  
        Patient characteristics are required control variables for predicting subsequent 
adenomas at surveillance examinations, especially gender and age. However, most 
studies do not take into account patient characteristics. A few studies have reported race 
and education to be associated with adenoma detection and features at CRC screenings. 
The related studies and findings are presented in Table 2.8. 
(1) Gender 
      Studies have reported a relationship between gender and adenoma detection. Males 
have a higher risk of advanced and non-advanced adenomas. The risk was nearly 2-fold 




2012). Males were 6.5 times more likely to develop advanced metachronous adenomas at 
surveillance colonoscopy (Bertario et al., 2003). A Japanese study also identified an 
association of neoplasias with male gender (HR, 1.8; 95% CI: 1.6-2.0) (Yamaji et al., 
2004). Males were more likely to have adenomas (OR, 1.44-1.59) (Thornton, Morris, 
Thornton, Flowers, & McCashland, 2007). However, males were less likely to have 
adenomas in the proximal colon (OR, 0.88; 95%CI: 0.79-0.98) (Lieberman et al., 2008).       
(2) Age 
        Some studies reported a relationship between age and adenoma detection, 
particularly older age. Advanced and non-advanced adenoma detection rates increase 
with age (Leffler et al., 2012; D. A. Lieberman et al., 2008; Thornton et al., 2007; Yamaji 
et al., 2004). Adults aged > 60 years were evaluated as a risk factor of finding an 
adenoma on surveillance examination (Jorgensen, Kronborg, & Fenger, 1995; Taniguchi 
et al., 2014; S. J. Winawer et al., 1993). Much older adults (aged >70) were about 4.1 
times more likely to have advanced metachronous adenomas at surveillance colonoscopy 
(Bertario et al., 2003) even if patients had begun screenings at the age of 40 years.  
(3) Other patient factors 
        Few studies here examined the impact of race, education, and insurance in adenoma 
findings. Thornton et al reported that blacks were less likely to have any polyp at 
screening colonoscopy (OR, 0.77; 95% CI: 0.70-0.84). However, they were more likely 
to have tumors (OR, 1.78; 95%CI: 1.14-2.77) compared to whites (Thornton et al., 2007). 
Combining of those factors, about 62% and 16% of black females and males had a higher 
risk of large polyps than white females and males (Lieberman et al., 2008). Education is 




a postgraduate education compared to whites with the same degree (RR, 1.29; 95%CI: 
1.09-1.54) (Laiyemo et al., 2010). Although blacks had a higher prevalence of advanced 
adenoma at initial examination, the risk of any adenoma recurrence was not different 
from whites (Laiyemo et al., 2013). 
2.4.7. Summary of literature findings 
        The totality of evidence suggests that adenomas with HGD, TVA/ villous adenomas, 
multiple adenomas, large adenoma, adenomas in the proximal colon, or serrated polyps 
are predictors of future advanced adenomas, non-advanced adenomas, or interval cancers. 
Particularly adenomas combining different features, such as having multiple adenomas 
with at least one of a large size, were more likely to develop advanced neoplasia 
(Vemulapalli & Rex, 2014). Although initial adenoma features can predict subsequent 
adenomas by multivariate analysis, there was a paucity of studies accounting for 
endoscopist-related or patient- related factors which might help to target patients before 
regarding the timing of surveillance colonoscopy.   
      Each indicator of colonoscopy quality has different roles: (1) quality of colon 
preparation and cecal intubation status are basic quality indicators for colonoscopy, and 
(2) adenoma detection rate (ADR) is a key index. The ADR may be associated with 
endoscopist skill and patient demographic characteristics (e.g., genetic factors, 
environmental factors, diet, cultures, etc.) (Hewett et al., 2010; Hewett & Rex, 2010; Lee 







Table 2.4 Risk of advanced neoplasia at surveillance among adults by adenoma characteristics at initial screening  
Primary author  
(year) 





US Retrospective cohort 
study 
697 < 3 Per 1 adenoma increased
*
: OR ,1.25/1.45 
≥ 1cm adenoma
*






1,287 3 >1cm adenoma (vs. <0.5cm): OR, 2.27 
Proximal (vs. distal): OR, 1.65 
Bertario 
(2003) 
Milan Prospective study 1,086 5(Mean) ≥ 2 adenomas (vs. 1 adenoma): OR, 1.6 
>2cm adenoma (vs. ≤ 1cm): OR,1.5 





US Meta-analysis 5 studies  3 ≥3 adenomas (vs. 1-2 adenomas) : RR, 2.52  
HGD (vs. LGD)
 
: RR, 1.84 
≥ 1cm adenoma(vs. < 1cm)
 
: RR, 1.39 
Villous (vs. no villous): RR, 1.26 
Lieberman 
(2007) 
US RCT  3,121 5.5 TA < 10mm (vs. no neoplasia) : RR, 2.56 
Villous (vs. no neoplasia)  :RR, 6.05 
HGD (vs. no neoplasia)
 
: RR, 6.87 
Laiyemo 
(2008) 
US RCT  1,905 5 HRA (vs. LRA)
 **
 : RR, 1.68 




Villous (vs. non-villous): RR, 2.43 
≥ 1cm adenoma (vs. < 1cm): RR,1.57 
HGD (vs. LGD)
 
: RR, 1.73 
Proximal (vs. distal): RR,1.58 
Martinez 
(2009) 
US Prospective study 8 studies 4(Median) HGD (vs. LGD)
 
: OR, 1.05 
≥2 adenomas (vs. 1 adenoma)
 #
 : OR, 1.39-3.87 
Proximal (vs. distal) : OR, 1.68 
TVA/villous (vs. TA)
 








Table 2.4 Risk of advanced neoplasia at surveillance among adults by adenoma characteristics at initial screening (continued) 
Primary author  
(year) 









: HR, 2.57 
HGD (vs. LGD)
 
: HR, 1.61 
≥3 adenomas (vs. 1 adenoma) : HR, 1.87  
Cottet 
(2011) 
France Retrospective cohort 
study 




Korea Prospective study  2,452 5 HRA (vs. LRA)
 **
 : HR, 5.95 
≥3 adenomas (vs. 1-2 adenomas) : HR, 3.06 
≥ 10mm adenoma (vs. < 10mm):  HR, 3.02 
Fairley 
(2014) 
US Retrospective study 25,635 10 ≥3 adenomas (vs. 1-2 adenomas) : OR, 2.4 
≥ 10mm adenoma (vs. < 10mm):  OR, 3.6 
HGD (vs. no HGD)
 
: OR, 4.3 
Villous (vs. no villous): OR, 3.7 
Vemulapalli  
(2014) 
UK Retrospective study 1,414 Over 10 ≥3 adenomas with 1 ≥  10mm(vs. 1-2 
adenomas <10 mm) : OR, 5.6-10.8 
≥5 adenomas with all < 10mm(vs. 1-2 




Dutch Retrospective study 2,990 6 ≥2 adenomas (vs. 1 adenoma) : OR, 1.6-3.3 
≥ 10mm adenoma (vs. < 10mm): OR, 1.7 
Villous (vs. no villous): OR, 2.0 
Proximal (vs. not proximal): OR,1.6 
Abbreviations: HGD, high-grade dysplasia; LGD, low-grade dysplasia; TA, tubular adenoma; TVA, tubulovillous adenoma.   
*
Outcome variable, advanced neoplasia includes tubulovillous adenoma, villous adenoma, high-grade dysplasia, carcinoma in situ, 
invasive cancer or size of 1cm or greater / 4 or more adenomas.
**
HRA, 3 or more adenomas or any advanced adenoma; LRA, 1 or 2 
non-advanced adenomas.
#











Table 2.5 Recurrence of any adenoma at surveillance among adults by adenoma characteristics at initial screening  
Primary author  
(year) 





US RCT 1,418 3 ≥3 adenomas (vs. 1 adenoma):OR,2.4 
>1cm adenoma(vs. ≤ 0.5 cm)
 
: OR, 1.6 
Van Stolk  
(1998) 
US RCT  479 4 ≥3 adenomas (vs. 1, 2 adenomas): OR, 2.25 
TVA (vs. TA)
 
: OR, 2.12 
Ji  
(2009) 
Korea Prospective study 667 3(Mean) ≥3 adenomas (vs. 1 adenoma): HR, 3.19 
Miller 
(2010) 
US Retrospective study 399 5 /6-10 ≥3 adenomas (vs. 1 adenoma) : OR, 1.4 





Japan Retrospective study 1,111 1/2 HGD :OR, 2.40 
Right-side colon :OR, 1.43 
≥ 10mm adenoma  :OR, 2.89 
≥3 adenomas: OR,6.12 
Abbreviations: HGD, high-grade dysplasia; LGD, low-grade dysplasia; TA, tubular adenoma; TVA, tubulovillous adenoma.   
*




















Table 2.6 Physician characteristics associated with quality of screening and surveillance examination 
Primary author  
(year) 
Location N Measures of 
quality 
Procedure volume of 
physician 




 Italy 12,835 Cecum intubation 
rate 
 
300-500 (vs. >500): OR, 0.82 






Canada 45,985 CRC rate - Rural surgeons (HR,3.38),  
Urban surgeons (HR,1.78), 
Internists (HR,2.25),  
Family practices (HR,3.01) 
Rabeneck (2010)
 *










US 328,167 PDR/ removal Middle annual colonoscopy 
volumes (vs. low volumes) 
#
:RR,1.1 
General surgery (RR,0.8), 
Colorectal surgery(RR,0.91), 
Family medicine(RR,0.86), 






Canada 14,064 CRC rate - Others
**
 (HR, 1.7-1.9) 
Bhangu  
(2012) 
UK 10,026 1.ADR 
2. PDR 
>100 colonoscopy per year 
 
(vs. no): OR, 1.22 
 




  Netherlands 4,738 1.Cecum 
intubation rate 
2.ADR 
- 1.Surgeons (OR,0.3),  
   Internists (OR,0.4) 
2.Surgeons (OR,0.2),  
   Internists (OR,0.71) 
Jiang(2013)
 *
 Canada 2,651 Polypectomy - Surgeons (OR,0.48, 0.73) 
Abbreviations: PDR, polyp detection rate; ADR, adenoma detection rate. 
*
Reference group for comparing types of endoscopy is gastroenterologists. 
**
Others include internists, general practitioners, and family physicians. 
#







Table 2.7 Gastroenterology fellow/assistant involvement in colonoscopy vs. adenoma detection rates (ADRs) 
Primary author (year) Type of assistant N (ADRs, %) 
  Without assistant With assistant 
Dellon (2008) GI endoscopy nurses - 3,631 (24.8%) 
Rogart (2008) GI fellows 126 (23%) 183 (37%) 
Peter (2010) GI fellows 2,895 (27.7%) 699 (34.3%) 
Xirasagar (2010) PCPs - 10,958 (29.9%) 
Aslanian (2013) Nurses 256 (58.6%) 336 (57.5%) 
Chalifoux (2014) GI trainees 339 (51%) 617 (63%) 



























Table 2.8 Patient characteristics associated with adenoma findings at screening or surveillance examination 
Primary author 
(year) 
Location N Measures Patient characteristics 
Winawer(1993) US 1,418 Adenoma Aged ≥ 60(OR, 1.4)  
Jorgensen(1995) Denmark 673 Adenoma Aged > 60(HR, 1.3) 
Bertario(2003) Milan 1,086 1.Metachronous adenoma 





2. Male(HR,6.5);  
    Aged >70 (vs. <60):HR,4.1 
Yamaji(2003) Japan 6,225 1.All neoplasias  
2.Advanced neoplasias 
1. Aged ≥ 40 (HR, 1.5-2.2);Male (HR,1.8) 
2. Aged ≥ 50 (HR, 3.6-5.5) 
Thornton(2007) US 46,726 1.Polyp 
2.Tumor 
1. AA (OR,0.77);  Age(OR,1.05); Male (OR, 1.59) 
2. AA (OR,1.78); Male (OR,1.44) 
Lieberman(2008) US 85,525 1.Large polyp 
2.Proximal large polyp 
1. Aged ≥ 50 (vs.<50): OR, 1.23-1.81; 
    Black female (vs. White female): OR, 1.62; 
    Black male (vs. White male): OR, 1.16 
2. Male (OR,0.88);  
    Aged ≥ 60 (vs.<50): OR, 1.23-1.81 
Imperiale(2008) US 2,983 Adenoma Male (HR, 1.92) 
Laiyemo(2010) US 60,572 Adenoma Black, postgraduate (vs. whites, postgraduate ): RR, 1.29 
Leffler(2012) US 2,139 1.Adenoma 
2.Advanced adenoma 
1. Female (OR, 0.77); 
    Increase patient age per year (OR, 1.04) 
2. Increase patient age per year (OR, 1.03) 
Tanignchi (2014) Japan 43,195 Adenoma Age≥ 65(OR, 1.38) 
*




2.5 Prediction of subsequent adenomas by baseline adenoma status  
This section reviews the literature on the timing of surveillance CRC screening, and 
adenoma findings at baseline examination that predict surveillance findings. Using 
previous screening information to predict the probability of high-risk findings on later 
examinations can help to optimize the finding of surveillance appropriately (Loberg et al., 
2014). Adenoma features are classified into high-risk, low-risk, and average-risk groups. 
The main concerns are whether any advanced adenoma predicts advanced adenoma 
findings at surveillance. However, negative findings at initial colonoscopy do not 
guarantee that patients will not develop adenomas at surveillance. 
2.5.1. Findings of serrated polyp at the surveillance colonoscopy based on present at 
baseline examination 
      Having serrated polyps is a rare colorectal condition associated with higher CRC risk, 
and their polyps are often sessile serrated adenomas/ polyps (SSAs/Ps). A recent study 
reported that recurrent sessile serrated adenomas or polyps occurred in 68% of patients at 
surveillance colonoscopy (Edelstein et al., 2013). Another study reported 15% of the 
SSA/P patients developed subsequent CRCs or adenomas with high-grade dysplasia (Fu, 
Qiu, & Zhang, 2014). 
2.5.2. Adenomatous polyp at surveillance colonoscopy associated with adenomas at 
baseline examination  
       The findings at initial colonoscopy are associated with the findings at surveillance. 
Risk stratification of adenomas has been reported. Four studies in the US and two studies 
from Korea and the Netherlands reported on recurrence of adenomatous polyps based on 




studies had differing approaches with regard to demographics, study design, and findings 
at surveillance colonoscopy as related to findings at the initial colonoscopy. Risks based 
on adenoma status are defined similarly: (1) high-risk is defined as having advanced 
adenomas, including high-dysplasia, villous or tubulovillous histology, size ≥ 1 cm, ≥3 
non-advanced adenomas, and invasive carcinomas, (2) low-risk is defined as non-
advanced adenomas, including 1 to 2 non-advanced adenomas, and (3) normal results are 
defined as hyperplastic polyps (not adenomas) or no polyp. The finding of studies on the 
percentage of adenomas found at surveillance colonoscopy by risk-level at baseline 
screening in the US and others are summarized in Table 2.9 and Table 2.10, respectively. 
(1) Findings in the US 
       One of the studies examined a sample of patients in the Prostate, Lung, Colorectal, 
and Ovarian (PLCO) cancer screening trial with surveillance colonoscopy use based on a 
history of adenoma. Study criteria for eligible patients included no current treatment for 
cancer and no known prior cancer of the colorectum, prostate, lung, or ovaries. Those 
patients were classified into 4 groups based on findings at the initial colonoscopy: (1) 
advanced adenoma (AA), (2) non-advanced adenoma (NAA), (3) non-adenomatous 
polyps (NAP), and (4) no polyp. There were 2,607 patients who met the requirements and 
had surveillance colonoscopy within 6 months to 10 years from the baseline colonoscopy. 
Significant findings are that around 19% of individuals with advanced adenomas found at 
baseline colonoscopy had adenoma recurrent, but recurrence rates were fairly constant 
from 1 year through 10 years after initial screening (Pinsky et al., 2009). 
        A randomized trial examined the findings at surveillance colonoscopy and evaluated 




Prevention Trial (PPT) and the PPT-Continued follow-up Study (PPT-CFS). Criteria for 
study eligible patients were: no history of surgical resection of adenomatous polyps, 
bowel resection, CRC, polyposis syndrome, or inflammatory bowel disease. The 
adenoma findings at baseline colonoscopy were grouped into low-risk and high-risk. Of 
1,905 individuals who had adenomas removed or had a diagnostic colonoscopy who 
participated in the PPT, 1,297 completed the follow-up Study. The results showed 
approximately 31% of individuals with high-risk adenomas also had high-risk findings at 
surveillance (Laiyemo et al., 2009).  
        The same author used the same data sources to assess the utilization of the risk-
stratification recommended by the 2006 guidelines. Ranges of 19.6% -46.2% of patients 
with a high-risk of adenoma status at initial colonoscopy have a recurrence of high-risk 
adenoma status at surveillance. However, they mentioned that adenoma-based risk 
stratification has limited predictability for findings at surveillance because demographic 
and lifestyle characteristics may affect the outcome (Laiyemo et al., 2008).            
          Another study used a different study design, but discussed similar issues in 
studying participants of an adenoma chemoprevention trial. All participants had 
screening and two surveillance colonoscopies at roughly 3 or 5 years as recommended. 
The risk of clinically significant adenoma recurrence was stratified based on the results of 
the first colonoscopy. The criterion for eligible patients was that they had a histologically 
documented large-bowel adenomas removed (n=564), and the study excluded those with 
an adenoma detected before their baseline colonoscopy and with cancer found at or 




low-risk, and no adenoma. About 18% of high-risk individuals had a recurrence of high-
risk adenomas (Robertson et al., 2009).    
        Finally, another retrospective study renewed 965 patients from a single specialty 
gastroenterology practice between 1985 and 2010, and then quantified the risk of 
advanced adenomas/ high-risk findings on surveillance colonoscopy. Patients with a 
family history of CRC, personal or family history of FAP or HNPCC, and second and 
third colonoscopies performed for any reason other than surveillance purpose were 
excluded.  
        Adenomas at the index colonoscopy were categorized into high-risk, low-risk, and 
non-neoplastic categories. They reported that high-risk findings at the second 
surveillance colonoscopy were best predicted by high-risk findings at the first 
surveillance (22% of cases) (Morelli et al., 2013).   
 (2) Findings from other countries  
       A study from Korea estimated the risk of high-risk findings at the second 
surveillance colonoscopy based on the prior two results. Eligible subjects included those 
who underwent screening colonoscopy and also completed their second surveillance 
colonoscopy. Those with CRC, polyp, inadequate bowel preparation or incomplete 
colonoscopy at baseline, invasive CRC, or history of inflammatory bowel diseases (IBD) 
were excluded. The results showed that high-risk findings at the second surveillance 
colonoscopy were significantly associated with high-risk findings from the previous two 




      Another study from the Netherlands also reported that adenoma characteristics are 
associated with recurrent colorectal neoplasia. They included patients with the first 
adenoma diagnosed and with follow-up data (van Heijningen et al., 2013). 
 (3)Findings of the US vs. other countries 
        Although those studies have different study designs and sample characteristics, the 
common finding is that adenoma features observed at previous examinations are 
associated with subsequent adenomas. A range of 18-31% of patients with high-risk 
findings at previous examinations has high-risk findings at the last surveillance 
examination. Moreover, a range of 5-10% of patients with low-risk findings at 
surveillance colonoscopy had low-risk adenomas at previous examinations in the US. In 
comparison, the studies from Korea and the Netherlands reported around 46% and 4% of 
adults with high-risk findings at follow-ups, respectively. The variance of these 
recurrence rates may be explained by the differences in surveillance guidelines and 
cultures which impact patients CRC risk behaviors. 
2.5.3. Likelihood of advanced neoplasia after negative screenings 
         Even for adults with negative findings at initial examination, the risk still exists to 
develop advanced adenomas because of missed lesions. Six studies examined the findings 
of advanced neoplasia after negative screenings, defined negatively as no polyp or 
adenoma found (Table 2.11).  







         Most of the studies involved surveillance screening at 5 years after negative 
findings at baseline examination. About 0.6-2.0% of these patients developed advanced 
neoplasia (Chung et al., 2011; Imperiale et al., 2008; Leung et al., 2009; Rex et al., 1996). 
Compared to these studies, one study had a more frequent surveillance interval of 3 years, 
and identified 0.8% of adults with negative findings having advanced neoplasia (Schoen 
et al., 2003). The studies with longer periods between follow-ups showed that risk 
findings occurred in 4.4-6.7% of cases per year of increased intervals (Brenner et al., 
2007). 
2.5.4. Summary of significant findings  
        These studies confirm the relationships between baseline findings and findings at 
surveillance colonoscopy. Information on baseline colonoscopy can predict subsequent 
adenomas. The risk of adenoma recurrence increases among individuals with high-risk 
adenomas at baseline examination, and adenoma recurrence is cumulative with a longer 
surveillance interval. In contrast, low-risk individuals did not predict low-risk or average-
risk at later follow-ups. Sometimes high-risk findings or interval CRC occur between 
scheduled examinations due to missed lesions at previous examinations. Therefore, using 
findings from all previous colonoscopies to determine the probability of high-risk 








Table 2.9 Findings of advanced neoplasia at the last surveillance colonoscopy by findings at baseline colonoscopy in the US (by risk 
stratification) 







Year  2009 2009 2009 2013 


























 19.3 30.6 18.2 22.0 
 Low-risk
**
 6.7 8.9 13.6 11.0 





 15.6 6.9 20.0 18.0 
 Low-risk
**
 5.7 4.7 9.5 8.7 
 No adenoma 3.9 2.8 4.9 - 
No adenoma High-risk
**
 11.5 - - - 
 Low-risk
**
 4.7 - - - 
 No adenoma 3.1 - - - 
*
PLCO: the Prostate, Lung, Colorectal, and Ovarian cancer screening trial; PPT: the Polyp Prevention Trial. 
**
High-risk is defined as 3 or more adenomas, tubular adenoma ≥ 10 mm, adenoma with villous histology, or high-grade dysplasia 
(HGD);  Low-risk is defined as 1-2 tubular adenomas <10 mm. 
#













Table 2.10 Findings of advanced neoplasia at the last surveillance colonoscopy by baseline colonoscopy findings in other countries 
(by risk stratification) 
Primary author  Suh 
 
Van Heijningen 
Year  2014 2013 
Location  Korea Dutch 






  852 1,482 
1
st





 46.2 4.0 
 Low-risk
**
 23.6 3.0 





 30.8 0 
 Low-risk
**
 32.5 1.0 
 No adenoma 1.0 
No adenoma High-risk
**
 23.1 - 
 Low-risk
**
 43.8 - 
 No adenoma - 
*
Subjects completed baseline colonoscopy and follow-up examinations. 
**
High-risk is defined as 3 or more adenomas, tubular adenoma ≥ 10 mm, adenoma with villous histology, or high-grade dysplasia 















Table 2.11 Findings of advanced neoplasia at the last surveillance colonoscopy after negative findings at initial screening
*
  




 Time interval  
(years) 
Advanced neoplasia (%) 
Rex (1996) 154 5 0.6 
Schoen (2003)         9,317 3 0.8 
Imperiale (2008) 1,256 5.3(Mean) 1.3 
Leung (2009) 401 5 1.4 
Brenner (2010) 533 11.9(Mean) 4.4-6.7
#
 
Chung (2011) 1,242              5 2.0 
*
Negative screening is defined as no any polyp or adenoma detected at baseline examination. 
**
Number of adults with negative findings at initial examination and rescreen at interval time. 
#




2.6 Original contributions of the current study, research gaps addressed 
       A colonoscopy is a high risk and costly procedure. It is not always perfect for 
preventing cancer despite the fact that it has been a dominant CRC screening modality in 
the United State since the 1990s. Having a surveillance colonoscopy administered 
appropriately after the initial examination is necessary. 
      Adenoma features are widely used to predict subsequent adenomas by risk 
stratification. Although adults with high-risk adenomas at initial screening are more 
likely to develop subsequent adenomas, adults with high-risk findings after negative 
screenings still occur. A possible explanation is that residual neoplastic tissue was left 
behind at prior examinations. About 20% of polyps and more than 70% of interval CRC 
cases were attributed to missed lesions (Ji et al., 2009; Pohl & Robertson, 2010; van Rijn 
et al., 2006). Moreover, high-risk adenoma characteristics (large adenomas, multiple 
adenomas, proximal adenomas, the presence of HGD, and TVA /villous adenomas) are 
associated with recurrence and advanced adenoma risk at follow-up features.  
         The pattern of surveillance practice is still highly rationale despite guidelines 
having been updated. Using only adenoma-based risk stratification in the current 
surveillance guidelines is a limitation to study recurrence due to underuse among high-
risk adults and overuse among low-risk adults (Laiyemo et al., 2008; Schoen et al., 2010). 
Underuse may harm at-risk adults, but overuse may result in reducing colonoscopy scene 
capacity for screening and surveillance (Johnson et al., 2015). Understanding the factors 
contributing to overuse or underuse of surveillance colonoscopy may help monitor 




        However, few studies have examined patient-related and endoscopist-related factors, 
which may also influence the effectiveness of screening/surveillance colonoscopy. 
Patient-related factors such as gender, age, and race are difficult to overcome. Also, other 
patient factors such as poor bowel preparation, knowledge, or adherence to guidelines 
influence the examination. Endoscopist-related factors are more related to endoscopy 
skills because of the differences in training and credentialing processes, and 
conscientiousness in performing the procedure which may cause inadequate polypectomy 
or lower adenoma detection rates (Hewett et al., 2010; Hewett & Rex, 2010; Johnson et 
al., 2015). Lack of knowledge or disagreements on guidelines may also drive non-
adherence to recommended practices by providers (Saini et al., 2009).   
         Overall, one comment explaining compliance of surveillance colonoscopies 
exclusively by adenoma risk-stratification at baseline colonoscopy. Other factors may 
contribute to non-adherence to timing recommendations despite guidelines having been 
widely published. Few data sources are available with information on patient and 
endoscopist covariates. Even if data sources have complete information, most suffer from 
selection bias, self-selected patients who may be more health-conscious or subjects 
overestimate findings. Therefore, surveillance utilization and factors to be targeted to 
improve guideline concordance should be aggressively identified. The contributions and 
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Figure 2.2 Conceptual framework: current research contributions and research gaps. 
*
High-risk is defined as ≥ 3 adenomas, tubular adenoma ≥ 10 mm, adenoma with 
villous histology, or high-grade dysplasia (HGD); Low-risk is defined as 1-2 tubular 
adenomas <10 mm. Abbreviations: TVA, tubulovillous adenoma; TA, tubular 
adenoma.
**




2.7 Contributions and knowledge gaps remaining despite recent studies 
on surveillance colonoscopy  
       This section discusses the significant findings of two related studies, the research 
gaps remaining, and the potential contributions from our study. A Netherlands study 
examined adherence to postpolypectomy surveillance guidelines in community-based 
clinical practice and evaluated the influence of a change in the guidelines on adherence 
rates (van Heijningen et al., 2015). This country has a universal healthcare access system. 
Another study identified the predictors of guideline-concordant surveillance colonoscopy 
recommendations and factors associated with overuse or underuse of surveillance 
colonoscopy (Kahn et al., 2015).  
2.7.1 Summary of approaches and findings of recent studies on surveillance colonoscopy 
use  
       The study from the Netherlands by Van Heijningen et al discussed adherence to 
recommended intervals in community-based clinical practice. Researchers studied 
patients with a first adenoma diagnosis from 1998 to 2002 and followed them up to 2008 
(n=2,997). The significant finding was that underuse relative to the postpolypectomy 
surveillance guidelines was high in the Netherlands population. Less than 25% of 
surveillance-eligible patients underwent surveillance at the appropriate time. The study 
showed significant proportions of delayed surveillance among patients with high-risk 
adenomas and early surveillance for patients with low-risk adenomas. The study did not 
evaluate the prevalence of surveillance among patients without polyps or with 
hyperplastic polyps. Therefore, inappropriate overuse was not studied. Another research 




hospital for surveillance and all other health purposes, the factors associated with low 
adherence rates were not explored. Finally, their outcomes do not generalize to the US 
population because the researchers used the Netherlands guidelines for their study. They 
used the 2002 guidelines which recommended that patients with one or two adenomas 
should have surveillance at six years, one year later than recommended by US guidelines 
(Snel & de Wolf, 1988).   
      A study from the USA by Kahn et al identified the predictors of guideline-concordant 
surveillance recommendations after adenoma polypectomies. Researchers studied 
subjects who underwent a polypectomy between 2011 and 2013 at an academic medical 
center’s safety-net health system in Dallas in the US (n=1,822). However, the study 
sample consisted of only those who were eligible for surveillance as per guidelines, and 
excluded those who were not eligible. They reported that nearly 25% of cases were not 
concordant with the surveillance guidelines. Patients with ≥ 3 adenomas, aged > 65 years, 
or with piecemeal resection of polyps at initial colonoscopy were more likely to have 
guideline-inconsistent surveillance colonoscopies. Although they determined the 
reasons/factors for low adherence to surveillance colonoscopy, the reported rates pertain 
to a safety net population covered by an academic medical center. Further the authors did 
not evaluate the appropriateness of surveillance colonoscopy timing given the 
recommended time intervals, and they did not account for provider factors in the 







2.7.2 Contribution of the current study  
        Based on the contributions of the reported studies some research gaps remain. This 
study examines the overall use of surveillance and premature repeat screenings of a total 
cohort of patients with an initial colonoscopy at a community-based endoscopy center in 
South Carolina.  It uses a large sample of 26,523 consecutive colonoscopies performed 
from September 4, 2001, to February 12, 2011 to study the pattern of surveillance 
colonoscopy use. We use the 2006 U.S. Multi-society Task Force guidelines to determine 
appropriate or inappropriate timing of surveillance and evaluate overuse, underuse and 
appropriate use among all patients and stratified by risk status at baseline colonoscopy. 
Inappropriate overuse will also be studied among patients without polyps or with 
hyperplastic polyps. More in-depth exploration of the relationship between timeliness of 
surveillance colonoscopy and baseline findings on polyp, patient, and colonoscopy 




CHAPTER 3  
METHODS 
      This chapter describes the research questions and methodology used in the study, 
including sample selection process and statistical analysis methods. There are 5 sections: 
(1) study questions, (2) data source and description, (3) study variables, (4) statistical 
methods, and (5) steps of data analysis. 
3.1 Study questions 
        To address the knowledge gap regarding surveillance based on prior literature, the 
following are the research objectives, study questions, and hypotheses. 
3.1.1 Research objectives  
       There are few data sources available to study surveillance frequency due to very few 
colonoscopy series reporting on surveillance colonoscopies. A few studies evaluated the 
status of surveillance colonoscopy use relative to the recommended guidelines, and the 
great variation in surveillance utilization. One reason could be differences in the 
populations covered by the colonoscopy series – with selection bias in some populations 
towards more educated or health-conscious subjects rather than randomly selected 
members of the general population as in a randomized clinical trial or academic systems. 
The consistency of surveillance frequency with the professional society recommendations 




       Studies that examined the utilization of surveillance colonoscopy have not reported 
on patient-related or endoscopist-related factors that may affect the risk of colorectal 
polyps’ recurrence, which drives surveillance timing decisions. The lack of this 
information limits the ability to study surveillance timeliness adjusted for polyp risk 
factors. Although a recent study documented an influence of a change in colonoscopy 
guidelines on practice, they did not examine the reasons that may affect the findings of 
surveillance colonoscopy (van Heijningen et al., 2015). Our study will address this gap. 
Another study documented that patients with ≥ 3 adenomas, aged >65 years, or with 
piecemeal resection of polyps at initial colonoscopy were more likely to have guideline-
inconsistent follow-ups. However, this study was mainly based on guideline 
recommendations and not all categories of patients (Kahn et al., 2015).          
      Therefore, the study research objectives are as below. It will use the data on initial 
colonoscopies to evaluate the appropriateness of surveillance use and timeliness relative 
to 2006 joint guidelines of the U.S. Multisociety Taskforce Guidelines [the American 
College of Gastroenterology (ACG) and the American Society for Gastrointestinal 
Endoscopy(ASGE)] (Winawer et al., 2006).  
     Study objectives: 
(1) To compare the appropriateness of surveillance colonoscopy timing at a major 
endoscopy center in SC among patients with an initial colonoscopy in the pre-
2006 period (pre-guideline) vs. 2006 and later, relative to the recommended 
surveillance intervals. The appropriateness is determined based on concordance of 




(2) To study the demographic, insurance and polyp-related factors at initial 
colonoscopy associated with the likelihood of timely surveillance.  
        To address these objectives, the study will mainly use the adenoma status (advanced 
adenoma and non-advanced adenoma), adenoma features (number, size, location, and 
histology), and period relative to guideline date (pre-2006, and 2006 and later) of these 
variables at initial colonoscopy will be used to explore the relationship with timely 
surveillance. 
3.1.2 Research questions 
       The original contribution of this work and how it addresses the research gaps have 
been explained in the previous chapter. The study purpose is to evaluate the impact of 
professional society guidelines on practice at a setting that is highly invested in high-
quality colonoscopy services as evidenced by very high CRC prevention among its 
screening colonoscopy clients compared to almost any other practice-based cohort 
documented in the literature. It has to achieve CRC prevention rates similar to the only 
clinical trial documented in the literature. Given the quality focus of the center, we seek 
to study the impact of the 2006 guidelines on the center’s surveillance or re-screening 
frequency. Before 2006, there were no official guidelines firmly recommending timings 
of surveillance based on characteristics of patients and polyps found at initial screening. 
The study will address the following research questions to achieve the objectives.  
(1) Is the timing of surveillance colonoscopies relative to the 2006 recommended 





(2) Are the post-2006 repeat colonoscopy procedures concordant in timing with the 
2006 guidelines? 
(3) Is the timing of surveillance associated with initial adenoma status, adenoma 
features, and  patient-related factors, and how does this differ in the pre-2006 
period vs. post-2006 and later? 
3.1.3 Research hypotheses 
      Those research questions are studied by testing the following hypotheses: 
(1)Hypotheses on the timing of surveillance colonoscopies at guideline date 
a. The surveillance colonoscopy interval is different among patients with initial 
colonoscopy in the pre-2006 period compared to those screened 2006 and later 
after adjusting for baseline adenoma features. (We include patients with an initial 
colonoscopy in 2006 in the post-guideline group because their earliest possible 
surveillance would be in 2007 when guidelines were operational.)  
b. Predictive factors for the timing of surveillance colonoscopies relative to baseline 
colonoscopy in terms of adenoma features and demographic characteristics will 
be different for patients with initial colonoscopy before 2006, and those of 2006 
and later. 
(2) Hypothesis on the predictors of timely surveillance colonoscopy  
a. The likelihood of appropriate timing of surveillance colonoscopy is associated with 
initial adenoma status, adenoma features, patient demographic characteristics, and 




3.2 Description of methods 
        The section introduces the data source and builds the study structure based on 
research objectives. The sample selection process is also presented. 
3.2.1 Data source 
         Data for the study comes from a licensed ambulatory surgery center for endoscopy, 
South Carolina Medical Endoscopy Center (SCMEC), in Columbia, South Carolina, now 
known as Carolina Colonoscopy Center (CCC). Data was extracted on colonoscopies 
performed from September 4, 2001 to February, 2011. A notable feature is that the 
Center mainly uses primary care physicians (PCPs) to perform procedures. About 72.7% 
of procedure were done by PCPs. Involving PCPs can help expand colonoscopy capacity 
to meet the demand for screening colonoscopy. The center also uses a unique protocol. 
One feature is search and removal of polyps during both scope insertion and withdrawal. 
The center has documented higher CRC prevention rates than other community-based 
centers, and comparable to that of the only clinical trial in the literature (Xirasagar et al., 
2010; Xirasagar et al., 2015). Shifting some of the screening workloads to PCPs may 
enhance the US populations access to cancer prevention if they have the proper training. 
In this study, ≥25% ADR was achieved by PCPs, 36.6% among males and 27% among 
females, exceeding the performance benchmark of the U.S. Multisociety Task Force (Rex 
et al., 2015; Xirasagar et al., 2015). 
       Post-training, the procedure performance protocol, and hands-on technical support 
provided to PCPs compensate for potential skill deficiencies of PCPs due to lack of 
formal gastroenterology training (They do not have pre-training). The center’s training 




colonoscopy. It ensures hands-on supervision and achieves participation by a credentialed 
expert by the University of South Carolina Medical School teaching hospital for the first 
140 procedures of the PCP-in-training. The training procedure number is identical to the 
ASGE-specified number of procedures for hospital credentialing (Faigel, Baron, Lewis, 
Petersen, & Petrini, 2007). At the center, the supervising specialist/expert is a 
gastroenterologist, colorectal surgeon, or the colonoscopy-credentialed director of the 
center’s colonoscopy training program, an internal medicine specialist with extensive 
experience in independently performed colonoscopies board-credentialing. The 
specialist/expert trains PCPs, providing hands-on endoscope management to advance the 
scope through the colon, tip manipulation to expose mucosal fields hidden in the colonic 
folds, viewing the video screen to coach the trainee on identifying tissue abnormalities 
and polyp recognition, and directing the performing of the patient and endoscope to 
enable safe and complete polypectomies. Hand on assistance is gradually reduced until 
the PCP is fully proficient with these operations and achieves mastery in the above skills 
over the 140 training procedures. Prior to completing 140 procedures, the manual 
assistance is gradually replaced by verbal assistance to help navigate flexures, difficult 
colonic segments, and/ or diverticula.  
       Post-training, the PCP performs procedures without specialist oversight. However, 
an expert is always available on-site while any PCP is performing at the center to provide 
rescue assistance. The specialist’s rescue assistance may be navigational or therapeutic 
when called for by the PCP, particularly to safely remove large or vascular adenomas, 




was started in 2001 and 54 PCPs performed colonoscopies at the center as of February 12, 
2011.  
        The center has implemented a polyp detection-maximizing protocol that has been 
updated regularly consistent with professional society guidelines and based on findings of 
published studies since 2001 (Sweeney & Lloyd, 2007; Xirasagar et al., 2010). The 
procedure protocol requires a 2-person technique for all PCPs since 2001. The center also 
encourages the use of the 2-person technique by colonoscopy-credentialed specialists and 
experts (bringing their cases to the center or hired by the center as back-up experts). The 
main features of the colonoscopy protocol at the CCC are: “(1) an endoscopy technician 
advances the colonoscope while the physician manipulates the scope tip for polyp search 
and removal. This can minimize the missing of polyps and ensure more persons watching 
the video screen for polyps; (2) at least 3 additional persons view the video screen to 
identify abnormal areas; (3) polyp search and removal takes place since March 2006 
during both the insertion and withdrawal phases; (4) propofol sedation was implemented 
to replace the conventional midazolam-meperidine combination sedation. The advantages 
of propofol sedation are that enable vary rapid induction of deep sedation and rapid 
recovery. Because there is more efficient utilization of the endoscopist’s time, it can 
reduce additional costs of the associated staff and infrastructure while patients’ gradual 
recovery with midazolam-meperidine or others (Cohen et al., 2007). Intravenous propofol 
is administered by a nurse-anesthetist; (5) Gradual insertion and circumferential 
withdrawal which is 6 minutes or greater of the colonoscope is done to maximize 
mucosal surface inspection. In preoperative preparation, patients received a phone call 




al., 2015). In addition patient positioning assistance to enable complete targeting of 
abnormal tissue for safe and complete removal or destruction in place is an important 
function served by the additional personnel in the room, especially the assisting 
endoscopy technician and the nurse anesthetist.  
3.2.2 Study design and structure 
        This is a retrospective cohort study to study the timing of surveillance colonoscopy 
as related to the initial examination. Data for this study comes from a total of 26,523 
procedures performed by the 54 PCPs and 5 experts at the center from September 4, 2001, 
up to February 12, 2011. The study objectives are to evaluate the relationship between the 
timing of surveillance and patient, colonoscopy procedure, and adenoma characteristics at 
baseline colonoscopy (Figure 3.1).  Hypothesized factors affecting surveillance timing 
are baseline adenoma status, adenoma features, patient characteristics, and professional 
society guideline date relative to the initial colonoscopy. Adenoma status includes 
advanced adenoma and non-advanced adenoma. Adenoma features that would influence 
surveillance timing are the presence of advanced adenoma features, which are the number, 
size, location, and histology (tubular, tubulovillous /villous, hyperplastic, or dysplasia 
features). Patient characteristics include gender, age, race, and insurance status. Because 
specific and detailed surveillance guidelines were established in 2006, comparison of 
surveillance timing between screening colonoscopies pre and post-guidelines is important. 
The time interval to surveillance is the key variable of interest for this study.  
3.2.3 Study sample selection and preparation of data 
         The Patient, Polyp, and Procedure datasets were linked by the procedure identifier 




procedures of the same patient. To populate missing data in several fields and resolve 
discrepant information between datasets, over 10,000 patient charts were reviewed 
manually. Updates were done in 2011, 2012, and 2014 and will be continued in 2016 to 
populate any other missing data. After merging the datasets and resolving discrepancies 
as mentioned above, duplicate entries of procedures were removed. Some variables were 
recoded from a text format into categorical form, and some categories were regrouped. 
Variables for which recording was done included: dysplasia level, pathology text, and 
pathology results. Pathology results were updated again in October 2012 because of 
missing data for polyps during a certain period due to alternate fields used by temporary 
CCC staff. 
     After updating, the final datasets for analysis were:  a) Procedure dataset which had 
patient characteristics and procedure information, and b) Polyp dataset which included 
colorectal segment-wise polyp histology. Polyp ID or procedure ID was used to link to 
patient characteristics. Each patient has unique procedure ID in a procedure, which can 
be used to link procedure information between Polyp and Procedure datasets. Figure 3.2 
shows the relationship of two datasets for linking procedure information in a patient. 
        A total of 26,523 colonoscopies were performed from September 4, 2001, to 
February 12, 2011. Of those 997 procedures were 3
rd
 or higher order procedures of a 
single individual. The next step was to designate the second procedure is done within 6 
months of the first colonoscopy as the first procedure (n=255) and assign their 3
rd 
order 
procedures to become 2
nd
 or surveillance procedures. Then, we integrate both polyp 




almost always due to the incomplete or unsatisfactory colonoscopy for whatever reason 
(Schoen et al., 2010; van Heijningen et al., 2015; Winawer et al., 2006).  
       The remaining 25,271 procedures were considered for the study. There were 20,912 
adults with a first procedure. Of these, 4,359 had a second procedure more than 6 months 
after the first procedure (Figure 3.3). Of patients with an initial colonoscopy, we excluded 
2,343 adults due to a) being aged below 40 years (not within the age group normally 
expected to undergo the adenoma-cancer sequence), aged more than 74 years (not 
recommended for routine screening and surveillance as per standard guidelines). We also 
excluded those with cancer at baseline procedure (n=103). This led to a potential sample 
of patients is 18,466. However, of these patient 1,569 had not yet completed the 
recommended surveillance interval as per the 2006 guidelines, as of February 11, 2011. 
The surveillance recommendation recommends that adults with different risk 
adenomas at initial colonoscopy should undergo surveillance examination at <1-year, 1-
year, 3- year, and 5-year intervals, respectively. Based on these criteria 1,569 patients 
were excluded. We allowed an additional 6 months over the recommended intervals to 
classify patients as surveillance completion eligible, as documented in the literature (van 
Heijningen et al., 2015). After exclusions, the study sample consisted of 16,897 eligible 
adults with a first procedure, of whom 4,234 eligible patients for surveillance. 1,793 of 
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Figure 3.1 Study conceptual framework: predictors of surveillance time interval 





















Procedure dataset: each patient 
may have several procedures  
 
 Procedure ID 
 
 Patient ID 
Polyp dataset: each polyp’s 
histology was show separately  
 
 Polyp ID 
 
 Procedure ID 
 
Summed each polyp’s information 
by procedure ID in Polyp dataset, 
and then merge with Procedure 
dataset by procedure ID 





































 procedures for 20,912 patients  
255 had 2
nd
 procedure within 6 months, data merged 
into 1
st
 procedure   
20,912 1
st
 procedures 4,359 2
nd
 procedures 
Excluded patients  
(4,015 for 1
st
 procedure/343 for 2
nd
 procedure): 
2,343/307 aged < 40 or ≥ 75 years  
103/36 with carcinoma  
1,569/0 patients no 2
nd
 procedure due to not    
              completing recommend surveillance interval  
  
 




 2,039  
12,571 not eligible for surveillance 
(Hyperplastic polyp or no polyp) 
Done early 
 1,793  
Not done  
10,778  
 
92 without histology  
 
1,045 hyperplastic polyp 





 or higher order procedures for 800 patients  
(1) AA: 77 procedures for 57 patients  
(2) NAA: 423 procedures for 332 patients 
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(4)No polyp: 247 procedures for 202 patients 
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Figure 3.3 Identification of study eligible patients with baseline and first surveillance 
colonoscopy. Abbreviations: AA, Advanced adenoma; NAA, Non-advanced adenoma; 





3.3 Study variables  
         This section describes the dependent, independent, and control variables of interest. 
All study variables of interest are summarized in Table 3.3 and 3.4, showing variable 
names, description, variable categories, and attributes. 
3.3.1 Dependent variables of interest and definition  
        The time interval to surveillance colonoscopy is our key variable of interest. It is 
defined as the interval from initial colonoscopy to the second colonoscopy. It is 
calculated from the database variable Procdate, the procedure dates of baseline and 
second colonoscopy. The calculated interval is named InterTime. Patients with a 
Procdate each for baseline and surveillance colonoscopy are those who had surveillance. 
Otherwise, Surveillance = zero (no surveillance).  
        The third variable is appropriate surveillance, defined by the USMSTF on Colorectal 
Cancer (ACG and ASGE keep expand joint guidelines) of 2006. Table 2.2 of chapter 2 
presents the guidelines for various risk groups based on screening colonoscopy findings. 
To summarize, the guidelines recommend 2-6 months for patients with sessile adenomas 
are removed piecemeal, 1-year surveillance for patients with hyperplastic polyposis 
syndrome or > 10 adenomas, 3-year surveillance for patients with 3-10 adenomas, ≥ 1 cm 
adenoma, or any adenoma with villous features, or high-grade dysplasia, 5-year 
surveillance for patients with 1 or 2 small tubular adenomas or any adenoma without 
advanced features, and 10-year surveillance for patients with small rectal hyperplastic 
polyps or normal tissues (hyperplastic or no polyp). The updated guidelines were 




        We defined the timing of surveillance colonoscopies as appropriate if the 
surveillance was within a range of ±3 months for the ≤ 1-year surveillance group and ±6 
months for ≥ 2-year surveillance time interval as per recommendations. The allowance of 
3 or 6 months before or after is consistent with the documented literature on community-
based series (van Heijningen et al., 2015). Those with surveillance earlier than these dates 
were classified as Overuse and later than these dates as Underuse. If patients had multiple 
polyp characteristics, the most severe one is used as the main indicator for determining 
time intervals. The corresponding appropriate surveillance intervals followed with the 
2006 guidelines and are presented in Table 3.1 (Winawer et al., 2006). We grouped 
different time intervals as per guidelines into 5 levels: <1-year surveillance, 1-year 
surveillance, 3-year surveillance, 5-year surveillance, and 10-year rescreening. Patients 
were classified into these groups under the variable, TimeGroup. For guideline-
concordance, the variable was coded into Overuse, Appropriate, Underuse, and No need 
for surveillance, called TimelySur. The overall compliance with timely surveillance 
colonoscopy was regrouped into guideline-inconsistent, and guideline-concordant, under 
the variable, GuideConcordant.      
3.3.2 Independent variables of interest and definition 
        There are three key predictor variables of interest. These are adenoma features at 
baseline, guideline date (pre-2006 vs. 2006 and beyond), and insurance status.  
(A)Adenoma related variables at baseline colonoscopy 
1) Presence of adenoma/ advanced adenoma/ polyp  
        We identified patients who had an adenoma or polyp detected at surveillance 




to the patient. All polyp information is documented in the Polyp dataset. If a 
patient ID exists in the Polyp dataset, it indicates this patient had a polyp. If the 
polyp was a histological adenoma, these patients were coded as” yes” for the 
variable “Adenoma” in the Procedure dataset. If a patient ID was not found in the 
Polyp dataset, or if the polyp showed normal tissue or hyperplastic tissue the 
patient was coded as” no” for the Adenoma variable.  
       A similar method was used to create a variable for the presence of advanced 
adenoma and any polyp, called AdvAdenoma and Polyps, respectively. The 
presence of advanced adenoma is defined as yes/no, yes=at least one advanced 
adenoma was found. Advanced adenoma is defined as villous features, the size of 
1 cm or more, high-grade dysplasia, or early invasive cancer by Winawer et al 
recommendations (Winawer & Zauber, 2002). We defined another variable as 
AdvAdenomaPlus to add patients of a recently added high-risk category, these 
with ≥ 3 adenomas. Polyp presence is defined as yes/no. Yes= at least one polyp 
was found which were not normal tissues. Finally, we categorized patients by the 
most advanced adenoma found at baseline colonoscopy: advanced adenoma, non-
advanced adenoma, and no adenoma, called AdenoStatus. 
2) Number of polyps/adenomas (summarized at patient/ procedure level) 
          The number of polyps found in the patient was summarized within each 
patient using the patient ID in the Polyp dataset. The count of polyps was summed 
into the Procedure dataset, called SumPolyp by patient ID (using only hyperplastic 
or adenomatous polyps to count; polyps found to be of normal tissue of any kind 




SumAdvAdenoma were created using a similar method. Another variable, polyp 
quantity is available, the total number of polyps found in the same colonic 
segment. These were summed across hyperplastic and adenomatous polyps and 
called SumPolypQuantity in the Procedure dataset. We also summed adenomatous 
polyps only to separate variable, called SumAdenoPolypQty. We created a 
categorical variable, in the polyp dataset AdenoPolypQty with 3 levels: no 
adenoma, 1-2 adenomas, 3-6 adenomas, and ≥ 7 adenomas.  
          3) Largest adenoma size (coded at the level of each adenoma) 
    The size of the adenoma was extracted from the Polyp dataset, polyp size in 
millimeters, called Polypsizemm. It was merged into Procedure dataset based on 
procedure ID, and the size taken in was based on hierarchically ordering all polyp 
size of the patient and selecting the largest adenoma. The largest adenoma size was 
categorized into ≥ 10 mm, 5.1-9.9mm, and ≤ 5mm, under the variable, AdenoSize.  
          4) Polyp anatomic location 
        The anatomic location of the polyp was extracted from Polyp dataset, which is 
PolypLocation. It is the original variable from primary data from the center, used to 
create the intermediate variables. The definition of the left colon is a location in the 
splenic flexure or descending colon. The location was defined as right if located in 
the cecum, ascending colon, hepatic flexure, or transverse colon. The remaining 
locations were defined as rectum and sigmoid if located in the rectum and sigmoid, 
respectively.   
       Two variables were created in the Polyp dataset for identifying: (1) The 




adenoma. We created a variable for the location of largest adenoma, using three 
intermediate variables, PolypLocation, Adenoma, and LargestPolyp. LargestPolyp 
was created to identify the size of the polyp by hierarchical order in a procedure. 
Another intermediate variable was created to produce the number of locations with 
adenomas, PolypLocation. Those new variables were summarized at the procedure 
level based on procedure ID, called LargAdenoLoc and SumNumLocAdeno, 
respectively. LargAdenoLoc had four categories: “Largest adenoma located in the 
right colon”, “Largest adenoma located in the left colon”, “Largest adenoma located 
in the rectum colon”, and “Largest adenoma located in the sigmoid colon”. 
SumNumLocAdeno was categorized into 2 levels: adenomas at 1-3 locations, and 
adenomas at 4 locations.  
         5) Variables on histology of the polyp (tubular, tubulovillous/villous adenomas, 
polyps with dysplasia features, and hyperplastic polyps) 
   The polyp characteristics were extracted from the Polyp dataset, from the 
fields of Pathologytext and Path_result (These two variables fields were used by 
the center to record histology during different time periods or a study period). Data 
from both fields were drawn into a new intermediate Polyp_result variable with 
three values, tubulovillous/villous, hyperplastic, and tubular. For 
tubulovillous/villous and tubular adenoma, we also used the adenoma variable to 
capture, called TubVillous and Tubular.  A new variable HyperPolyp (yes/no) was 
recoded directly from Polyp_result to designate whether it was a hyperplastic polyp.  
    A dysplasia variable was coded from Pathologytext and Path_result, which 




dysplasia not mentioned but stated to have dysplasia), Mild or no dysplasia, 
Moderate, Severe, Carcinoma in situ, Invasive carcinomas, Carcinoid tumor, and 
Probably invasive. We also coded patients with 2 or more advanced adenoma 
characteristics, which include ≥ 1cm adenoma, tubulovillous/villous adenomas, or 
any adenoma with high-grade dysplasia. The variable AdcAdenoFea (yes/ no) was 
created.  
         (6) Variable in polyp type (based on U.S. MSTF surveillance guidelines, Winawer 
et al 2006)  
                 Variables on polyp type were created to align with the 2006 guidelines of 
surveillance colonoscopy timing. (1) small (< 1cm) rectal hyperplastic polyp, 
SmallRtHP, (2) 1 or 2 small (<1 cm) tubular adenoma with low-grade dysplasia, 
TwoSmallTA, (3) 3-10 adenomas, ThreeToTenAdenoma, (4) ≥1 cm adenoma, 
BigAdenoma, (5) tubulovillous/villous adenomas, TubVillous, (6) high-grade 
dysplasia, HGD, (7) hyperplastic polyposis syndrome, HPPS, (8) > 10 adenomas, 
TenPlusAdenoma, and (9) sessile adenomas removed piecemeal, 
SessileAdenPiecemeal, respectively (Table 3.2). 









                    All those combinations were created from different source variables 
(TubVillous was mentioned earlier). SmallRtHP was coded based on HyperPolyp, 
Polypsizemm, and PolypLocation from the Polyp dataset. TwoSmallTA was coded 
from Tubular and Polypsizemm. ThreeToTenAdenoma and TenPlusAdenoma were 
coded from SumAdenoPolypQty. BigAdenoma was coded from Polypsizemm. 
Patients had high-grade dysplasia feature was coded from Dysplasia. HPPS was 
coded from HyperPolyp, Polypsizemm, and PolypLocation. Finally, patients with 
sessile adenomas removed piecemeal were coded from PeduncSessile and 
Destroyed. PeduncSessile was itself created from the text in the field, Morphology 
which has polyp morphological characteristics recorded by the performing 
physician, supplemented by additional notes from Pathologytext. The definition of 
FullDestroyed is: was the polyp completely removed in the procedure. All were 
extracted into the Procedure dataset based on the procedure ID where these new 9 
variables were created. These patients were coded as” yes” for each variable of they 
had those features.   
 (B) Variable to designate initial colonoscopy, pre- or post- 2006 guideline 
        Prevalence of surveillance guideline at the time of baseline colonoscopy was coded 
based on Procdate (procedure date at baseline colonoscopy) into a variable, 
PreGuideDate. If the initial procedure date was before 2006, PreGuideDate was coded 
“Pre-2006 period”; if the initial colonoscopy took place in 2006 and later, it was coded 






(C)Insurance status at baseline colonoscopy 
          Patient’s insurance information was collected at the time of initial colonoscopy 
from the original variable in the Procedure dataset, called Inscarrier. Insurance carriers 
were grouped into 4 groups: Medicare, Medicaid, private, and uninsured, called 
Insurance2. 
3.3.3 Control variables  
        Patient demographic characteristics were adjusted in the models to examine their 
associations with the timeliness of surveillance.  
(A) Patient demographic variables 
       Patient gender (female and male) was titled PatGender. Patient age was calculated 
from the patient’s date of birth extracted from the CCC’s administrative billing system, 
called PatAge. PatAge was recorded as a categorical variable, AgeGro into 3 age groups: 
40-49, 50-59, and 60-74 years. Patient race was coded as Whites, Blacks, Other or 
unknown, called PatRace. 
(B) Number of observation years available 
       It is defined as the interval from initial colonoscopy to the end of the study period. It 
is calculated from the database variable Procdate, the procedure dates of baseline and 













Table 3.1 Operational criteria definitions used for classifying surveillance colonoscopy 
timing since initial colonoscopy to define Appropriate timing, Underuse, and Overuse 
category
* 
 Interval recommendation 
(in years) 
No surveillance needed 
(time interval in years) 
Polyp types  Overuse Appropriate Underuse 
Normal tissues  
(include few hyperplastic 
polyps or no polyp) –Not 
eligible for surveillance 
10 <9.5 9.5-10.49 NA 
Small rectal hyperplastic 
polyps 
10 <9.5 9.5-10.49 NA 
  Surveillance timelines category  
(time interval in years) 
1 or 2 small (<1 cm) 
tubular adenomas with 
low-grade dysplasia 
5 <4.5 4.5-5.49 >5.5 
Any adenoma without 
advanced features 
5 <4.5 4.5-5.49 >5.5 
3-10 adenomas,  
adenoma ≥1 cm,  
any adenoma with 
villous features,  
or high-grade dysplasia 





1 <0.75 0.75-1.25 >1.25 
>10 adenomas 1 <0.75 0.75-1.25 >1.25 
Sessile adenomas that 
are removed piecemeal 
<1 - 0-0.75 >0.75 
*
Winawer et al 2006; Levin et al 2008.
 
**
Hyperplastic polyposis was defined by Burt and Jass for the World Health Organization 
International Classification of Tumors as: (1) at least 5 histologically diagnosed 
hyperplastic polyps proximal to the sigmoid colon, of which 2 are greater than 1cm in 
diameter, or (2) any number of hyperplastic polyps occurring proximal to the sigmoid 
colon in an individual who has a first-degree relative with hyperplastic polyposis, or (3) 
more than 30 hyperplastic polyps of any size distributed throughout the colon. Since our 
study did not have information on first-degree relatives, we included first and third 









Table 3.2 Study variable definitions used to create polyp types as the 2006 guidelines
*
: baseline colonoscopy 
Variable name Description Categories Attribute 
Adenoma characteristics    
Polyps Does this patient have any polyp?  No, Yes Dichotomous 
Adenoma Does this patient have any adenoma? No, Yes Dichotomous 




No, Yes Dichotomous 
SmallRtHP Any polyp is small (< 1cm) rectal 
hyperplastic polyp? 
No, Yes Dichotomous 
TwoSmallTA Is any 1 or 2 small (<1 cm) tubular 
adenoma with low-grade dysplasia? 
No, Yes Dichotomous 
ThreeToTenAdeoma Are any 3-10 adenomas? No, Yes Dichotomous 
BigAdenoma Is any ≥1 cm adenoma? No, Yes Dichotomous 




No, Yes Dichotomous 
HGD Is any adenoma with high-grade 
dysplasia? 
No, Yes Dichotomous 
HPPS Is any hyperplastic polyposis 
syndrome? 
No, Yes Dichotomous 
TenPlusAdenoma Are any >10 adenomas? No, Yes Dichotomous 
SessileAdenPiecemeal Any polyp is sessile adenomas that are 
removed piecemeal? 
No, Yes Dichotomous 
*
The polyp types were created as follow the guidelines by Winawer et al 2006. 
**
Advanced adenoma is defined as villous features, the size of 1 cm or more, high-grade dysplasia, 3 or more adenomas, or early 
invasive cancer. 
#
According to the 2006 guidelines, we mainly considered patients who had sessile adenoma that are removed piecemeal. Therefore, 










Table 3.3 Study variable definitions used in analysis: baseline colonoscopy (all variables at the patient level) 
Variable name Description Categories Attribute 
Patient characteristics    
PatGender Patient gender Female, Male Dichotomous 
AgeGro Patient age 40-49, 50-59, 60-74 Categorical  
PatRace Patient race Whites, Blacks, Other or unknown Categorical 
Insurance2 Insurance status Medicare, Medicaid, Private, 
Uninsured 
Categorical 
Colonoscopy characteristics    
PreGuideDate When does this patient take first 
procedure? 
Pre-2006 period, 2006 and later Dichotomous 
NumOfYrAvailable The number of years from initial 




Adenoma characteristics    
AdenoStatus The most advanced of adenoma found Advanced adenoma, Non- advanced 
adenoma, No adenoma 
Categorical 
LargAdenoLoc The location of largest adenoma found Right colon, left colon, rectum, 
sigmoid colon 
Categorical 
SumNumLocAdeno The number of locations with 
adenomas found 
1-3 locations, 4 locations Categorical 
AdenoSize The largest size of adenoma found ≥ 10 mm, 5.1-9.9mm, ≤ 5 mm  Categorical 
AdenoPolypQty The number of adenomas found in the 
same colonic segment 
1-2 adenomas,3-6 adenomas, ≥ 7 
adenomas 
Categorical 
AdcAdenoFea Any 2 or more advanced adenoma 
characteristics found? 











Table 3.4 Study variable definitions used in analysis: surveillance colonoscopy  
Variable name Description Categories Attribute 
SurveillanceStatus
*
 The status of surveillance colonoscopy 
by the end of study period 
Event = Yes or No Categorical 




TimeGroup Time interval (years) to surveillance/ 
rescreening colonoscopy by 2006 
guidelines 
<1-year, 1-year, 3-year, 5-year, 10-
year rescreening for overuse,10-year 
rescreening 
Categorical 
TimelySur Timing of surveillance colonoscopies 
with 2006 guidelines 
Overuse, appropriate, underuse, no 
surveillance needed 
Categorical 
GuideConcordant Does this patient have surveillance 











3.4 Statistical methods 
          This section describes the process of data management and analysis including 
statistical methods. The study used descriptive and inferential analysis. Finally, the 
preliminary findings on sample distribution are presented to assist further recoding of 
variables in answering the research questions. 
3.4.1 Data management and analysis 
       The study uses data on all colonoscopies conducted from September 4, 2001, to 
February 12, 2011, imported from the CCC’s Microsoft Excel databases. The primary 
datasets were Physician (no names imported), Procedure, Polyp, and Patient datasets 
(without patient identifiers except a numeric patient ID corresponding to the number on 
their medical record at CCC). The Procedure dataset consisted of data entered by CCC 
staff into Excel based on clinical procedure notes. Procedure data fields used for the 
study were based on raw variables: total procedure time (time of scope insertion, time out 
of anus, time of starting withdrawal), sequential number of the physician’s procedure if it 
was < 140
th
 for that physician, and cecum reached status; The Polyp data used are 
histology of the polyp, whether this polyp an adenoma, size, dysplasia level, whether the 
polyp was removed, how was the polyp removed, and location of the polyp. The Patient 
fields used were the patient age at the initial procedure date, gender, and race.     
        Data preparation on to satisfy the study objectives, for all patients with a first 
procedure up to February 12, 2011, first surveillance procedures if done is described in 
section 3.2. We excluded those who are not eligible for surveillance colonoscopy and 
those who did not have any second procedure due to not completing the surveillance 




examine associations between the dependent and independent variables of interest as 
defined earlier. SAS v9.4 was used.    
3.4.2 Descriptive statistics 
      Descriptive statistics are used to describe the patients, procedures, and polyps and to 
examine bivariate associations between the dependent and independent variables of 
interest. Chi-square and analysis of variance (ANOVA) are used. In the descriptive tables, 
distribution of patients, procedures, and polyps are shown using percentages for 
categorical variables and means with standard deviation (mean±SD) for continuous 
variables.  
 (1)Chi-square test 
      A chi-square test (X
2
) is used to determine whether there is a significant difference 
between the expected and observed frequencies in one or more categories.  
(2)Fisher’s exact test 
      The Fisher’s exact test is a statistical significance test used in the analysis of 
contingency tables. It is applied when we plan to conduct a chi-square test, but one or 
more cells have an expected frequency of 5 or less (Fisher, 1922). 
 (3)ANOVA test 
       The ANOVA test is used to analyze differences between group means and their 
associated procedure. It provides a statistical test of whether or not the means of several 
groups are equal, of generalizes the t-test to more than two comparison groups, using 






3.4.3 Inferential statistics  
      Inferential statistics is used to judge the probability that an observed difference 
between groups is not merely a matter of chance. Kaplan-Meier (KM) curves with log-
rank test, logistic regression model, and multinomial logistic regression model are used. 
(1) Kaplan-Meier (KM) curves  
      The original definition of the Kaplan-Meier curves was published for dealing with 
those incomplete observations with an incomplete event by the end of study period by 
Edward L. Kaplan and Paul Meier in 1958. Kaplan-Meier (KM) curves have become a 
familiar way of dealing with differing survival times (time-to-event), especially when not 
all the subjects continue in the study. In the use of KM curves, survival time does not 
need to relate to death as the event. The event may be any event of interest (Kaplan & 
Meier, 1958). It has also been applied to estimate the surveillance probability (getting a 
colonoscopy) or any adenoma recurrence by time to surveillance, using adenoma features 
at index screening (Huang et al., 2010; Schoen et al., 2010; van Heijningen et al., 2015).  
       In preparing the data for KM survival analysis, each subject is characterized by three 
elements: (1) their period in the study, (2) the status at the end of their time, and (3) the 
study group they are in. Time-to-event is defined as time duration for each subject having 
a beginning and an end anywhere along the timeline of the complete study. It can begin 
when the subject is enrolled into a study or when treatment begins (in this case initial 
colonoscopy date), and ends when the end-point is reached (surveillance) or is censored 
from the study for other reasons. Censoring occurs when the subject’s total time duration 
at risk for the event cannot be accurately determined, such as in the case of dropouts, lost 




cumulative probability of the event in a given length of time while breaking up time into 
many small intervals, which was used to calculate a step-wise estimate (Rich et al., 2010).          
      Based on these features, KM estimates can be applied to surveillance colonoscopy 
use, which is the simplest way to compute surveillance use over time, despite the 
challenge of subjects lost to follow-up in the study period. It is a nonparametric statistic 
used to estimate the surveillance function from lifetime data. The main purpose is to 
measure the fraction of patients who have surveillance colonoscopy over a certain 
amount of time after the initial colonoscopy in clinical practice. Our study estimated 
probability curves to compare the pattern of timing of surveillance colonoscopies relative 
to recommended intervals for patients with an initial colonoscopy in the pre-2006 period 
vs. post-2006(includes those with the first procedure in 2006). InterTime variable is our 
main dependent variable for comparison of surveillance colonoscopy use pre- and post-
guideline. The comparisons are also adjusted for the differences in patient gender, age, 
and race by time interval groups to surveillance colonoscopy.     
       The survival time is defines as the time lapsed from a defined starting point (initial 
colonoscopy in this study) to the occurrence of a given event (surveillance). Subjects who 
did not undergo surveillance are counted as right censoring since they may have 
surveillance in the future. Variable SurveillanceStatus was created to identify censoring 
status on surveillance colonoscopy use. It defined as an event (SurveillanceStatus 
variable=1) when patients had the second procedure by the end of the study period. 
SurveillanceStatus =0 if they had no second procedure until February 11, 2011. 
       The conditional probability of surveillance colonoscopy at any particular time (t) is 




𝑆(𝑡) = 1 −
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑐𝑜𝑚𝑝𝑙𝑒𝑡𝑒𝑑 𝑠𝑢𝑟𝑣𝑒𝑖𝑙𝑙𝑎𝑛𝑐𝑒 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑡
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑒𝑙𝑖𝑔𝑖𝑏𝑙𝑒 𝑓𝑜𝑟  𝑠𝑢𝑟𝑣𝑒𝑖𝑙𝑙𝑎𝑛𝑐𝑒 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑡
 
       Surveillance probability at time t is calculated as the product of the conditional 
probability till time t.  
(2) Comparison of Kaplan-Meier (KM) estimates: log-rank test  
              The log-rank test is the most common method to compare the difference between 
survival curves. Our study applied this test for comparing surveillance colonoscopy use 
by patients with the first colonoscopy in two different periods, pre-2006 period vs. 2006 
and later. Log-rank test is used to examine whether two periods are statistically different 
on probability of surveillance colonoscopy use. This test is to calculate the expected 
number of surveillance colonoscopy in the two periods (E1 and E2) against the actual 
total number of observed surveillance colonoscopy events (O1 and O2) in the two periods, 
respectively. The test statistic is as follow as:  







Where O1 represents the sum of the observed number of surveillance colonoscopy for the 
pre-2006 cohort and E1 represents the sum of the expected number of surveillance 
colonoscopy this cohort. Similarly, we can define O2 and E2 with the post cohort. 
      The test statistic and significance can be drawn by comparing the calculated value 
with the critical value, using chi-square tables, at one degree of freedom (Goel et al 2010; 
Rich et al 2010) (Goel, Khanna, & Kishore, 2010; Rich et al., 2010).  
 




 (3)Logistic regression model (Wang, Xie, & Fisher, 2009)  
        The logistic regression model is for binary outcome measures in non-hierarchically 
structured data. It has been used in many surveillance colonoscopy studies predicting 
adenoma recurrence, as mentioned in the prior chapter. Multinomial logistic regression is 
used to predict categorical placement in, or the probability of category membership of a 
multi-level dependent variable predicted by multiple independent variables. This model is 
also a simple extension of binary logistic regression to accommodate more than two 
categories of the dependent variable. Since multinomial logistic regression does 
necessitate consideration of the sample size, we should follow sample size guidelines 
which indicate a minimum of 10 cases per independent variable (Hosmer & Lemeshow, 
1989).    
        Statistically in logistic regression, the probability of “event” is usually converted to 
an odds ratio [p/ (1-p)], resulting in the following logistic regression or logit model:  
𝑙𝑜𝑔𝑖𝑡(𝑝) = log [
𝑝
1 − 𝑝




Where 𝛽𝑛 is the regression slope coefficient of the explanatory variable 𝑋𝑛 
The logit model can be expressed in terms of the probability of an event occurring: 
𝑝 = Pr(𝑦𝑖 = 1| 𝑋) =
exp (𝑧)
1+exp (𝑧)




Where z=𝛽0 + ∑ 𝛽𝑛𝑋𝑛
𝑛
𝑛=1 . Those equations called the logistic function have an S-shaped 
distribution, which signifies a non-linear relationship between the outcome probability 




       This study will use bivariate and multivariate logistic regression models to determine 
the factors that drive the likelihood of having timely surveillance. The main dependent 
variable is GuideConcordant, which is whether the surveillance colonoscopy is 
guideline-concordant.   
        Therefore, we mainly test the association between surveillance concordance and the 
variables of initial adenoma status, adenoma features (includes the location of largest 
adenoma, number of locations with adenoma, the largest size of adenoma, number of 
adenomas found in the same colonic segment, and with 2 or more advanced adenoma 
characteristics) and insurance status, adjusting for the remaining variables. The model is 
as follows:   
YGuideline-concordant (Yes vs. No) =β0+ β1×patient gender+ β2×patient age+ β3×patient race+ 
β4×insurance status+ β5×period relative to guideline + β6×adenoma status+ β7× location 
of largest adenoma+ β8× number of location with adenoma+ β9× the largest size of 
adenoma+ β10× number of adenomas found in the same colonic segment+ β11× 2 or more 
advanced adenoma characteristics+ ɛerror 
        Then, we use bivariate and multivariate multinomial logistic regression to determine 
the factors that drive the likelihood of timely surveillance. The main outcome is 
TimelySur, which is surveillance colonoscopy prevalence relative with the guidelines 
being overuse, appropriate, or underuse. It mainly tests the association between initial 
adenoma status, adenoma features (includes the location of largest adenoma, number of 
locations with adenoma, the largest size of adenoma, number of adenomas found in the 
same colonic segment, and with 2 or more advanced adenoma characteristics) and 




Since the outcome variables with 3 categories, we assign appropriate to be reference 
group. There are two models are used to discuss. The first model is to compare overuse to 
appropriate of surveillance colonoscopy, as follows:  
YTimely Surveillance(Overuse vs. Appropriate)  =β10+ β11×patient gender+ β12×patient age+ β13×patient 
race+ β14×insurance status + β15× period relative to guideline + β16×adenoma status+ β17× 
location of largest adenoma+ β18× number of location with adenoma+ β19× the largest 
size of adenoma+ β110× number of adenomas found in the same colonic segment+ β111× 2 
or more advanced adenoma characteristics+ ɛerror  
The second model will compare underuse to appropriate surveillance colonoscopy, as 
follows: 
YTimely Surveillance(Underuse vs. Appropriate)  =β20+ β21×patient gender+ β22×patient age+ β23×patient 
race+ β24×insurance status + β25× period relative to guideline + β26×adenoma status+ β27× 
location of largest adenoma+ β28× number of location with adenoma+ β29× the largest 
size of adenoma+ β210× number of adenomas found in the same colonic segment+ β211× 2 
or more advanced adenoma characteristics+ ɛerror 
3.5 Steps of data analysis  
       This section describes the plan for applying the above statistical methods in our study 
to answer the research questions. Statistical models are used to examine associations 
between the timing of surveillance colonoscopies (dependent variable) and independent 
variables of interest. For our two objectives, the following steps will be used for reporting 





3.5.1 Dependent and independent variables of interest 
       Time to surveillance colonoscopy is the dependent variable. Adenoma status, 
adenoma features (includes the location of largest adenoma, the number of locations with 
adenoma, the largest size of adenoma, number of adenomas found in the same colonic 
segment, and with 2 or more advanced adenoma characteristics) and insurance status are 
our key independent factors of interest. The control variables include patient 
demographics (gender, age, and race), and number of observation years available. P 
values of < 0.05 will be considered as statistically significant.  
3.5.2 Analysis steps for objective 1 
        Our first objective is to compare the observed timing of surveillance colonoscopies 
relative to the 2006 recommended intervals for patients with an initial colonoscopy in the 
pre-2006 period vs. 2006 and later. This section presents the preliminary frequency 
distributions to assess the feasibility of answering the research questions. 
       Identification of study eligible patients with a baseline colonoscopy showing 
exclusions from the full patient sample is presented in Figure 4.1. It presents the number 
with a second procedure by date of initial colonoscopy of the eligible initial 
colonoscopies. The criteria of define appropriate surveillance interval as per guidelines 
are shown in Table 4.1. Table 4.2 presents characteristics of the study population at 
baseline colonoscopy, including patient gender, age, race, insurance status, and other 
variables. The chi-square test will be used to examine the relationship of surveillance 
appropriateness with the guideline date (pre-2006 period, vs. 2006 and later).  
      Then, Kaplan-Meier (KM) curves will be used to estimate the surveillance probability 




periods relative to guideline date, and by recommended time interval groups based on 
findings baseline colonoscopy: ≤ 1-year surveillance, 3-year surveillance, and 5-year 
surveillance (Figure 4.2-4.4). Patients who do not qualify for surveillance had a 
premature second procedure will also be shown (Figure 4.5). Comparisons of 
characteristics between groups will be presented by the log-rank test.   
       The study will further examine the timing of surveillance colonoscopies relative to 
guideline-concordance among the pre-2006 period patients vs. 2006 and later patients, 
and by time interval groups at initial colonoscopy. Timing of surveillance colonoscopy 
will be stratified into 3 categories: overuse, appropriate, and underuse. A Pearson’s chi-
square or Fisher’s exact test will be used to compare the percentages with timely 
surveillance, overuse and underuse between pre-guideline and post-guideline cohorts 
(Table 4. 3).  
3.5.3 Analysis steps for objective 2 
       Our second objective is to study the factors that determine the likelihood of timely 
surveillance. We test our independent variables of interest associated with timely 
surveillance, adjusting for the remaining variables.  
        Characteristics of study subjects with a screening colonoscopy between September 4, 
2001 and February 11, 2010 are presented in Table 5.1.  Table 5.2 shows the percentage 
of surveillance-eligible patients with guideline-concordant surveillance relative to 
recommended guidelines (overuse, appropriate, late, and not done). We use the Pearson 
chi-square test to profile the study population by features at initial colonoscopy that are 
associated with surveillance use (Table 5.2). Then, we identify variables of interest that 
drive the likelihood of having a 2
nd




eligible patients after controlling for the remaining variables presented in Table 5.3 and 
5.4. Logistic regression results will be used.  
       Association of surveillance timing intervals with polyp, patients, and procedure-
related characteristics among surveillance-eligible who completed surveillance by 
recommended surveillance intervals are shown in Table 5.5-5.8. Linear regression results 
will be applied. The variables of interest associated with the likelihood of the timing of 
surveillance colonoscopy relative to recommended intervals after controlling for the 
remaining variables will be presented in Table 5.9. Since our primary outcome of interest 
has 4 levels, multinomial logistic regression will be performed. 
3.6 Preliminary reviews of sample distribution by key dependent and 
independent variables  
      The study presents the preliminary sample distribution by patient demographics, 
utilization of surveillance colonoscopy, time intervals to surveillance colonoscopy, and 
adenoma features at baseline colonoscopy (location of largest adenoma, number of 
anatomic locations with an adenoma, the largest size of adenoma, number of adenomas 
within the same colonic segment, and patients with 2 or more advanced adenoma 
characteristics). The distributions and the changes made to variable categories for final 
analyses, keeping in view cell sizes are shown below. 
3.6.1 Characteristics of study population and utilization of surveillance colonoscopy  
       Of 16,897 eligible patients with an initial colonoscopy, about 56.4% of patients had 
an initial colonoscopy in the pre-2006 period. All patients 4,016 (23.8%) had a second 
colonoscopy after a mean of 3.5 years (SD 1.7). Majority of patients were female (54.1%), 




were Black (51.9%). Having insurance coverage may affect the surveillance colonoscopy 
use. About 70.7% of patients had private insurance and 17.8% had Medicare coverage. 
The majority of the procedures were performed by PCPs (74.0%) (Table 3.5). Regarding 
surveillance colonoscopy use, patients with adenoma and advanced adenoma found at 
baseline colonoscopy had higher rates of repeat examinations (Table 3.6).  
3.6.2 Bivariate distributions relevant to objective 1 
       Study objective is to compare the timing of surveillance colonoscopies relative to the 
recommended surveillance intervals among the pre- and post-guideline cohorts. The time 
interval to surveillance is our main dependent variable. Table 3.7 presents timeliness of 
surveillance colonoscopy by recommended time interval groups. Among 4,234 eligible 
patients for surveillance, most of the patients did not have follow-up screening at <1-year 
(51.7%), 1-year (46.3%), and 3-year (48.9%) recommended time interval groups. The 
frequency of overuse and underuse which is not done surveillance colonoscopy are 
similar in 5-year groups. 1,793 of 12,571 total patients who are not eligible for 
surveillance have come back early. 
3.6.3 Bivariate distributions relevant to objective 2        
       Study objective 2 is to examine the factors associated with the likelihood of timely 
surveillance. Timeliness of surveillance is our key dependent variable, which is 
categorized into overuse, appropriate, and underuse. We pool the various polyp/adenoma 
patient groups into the 3 categories based on each patient recommended time and 
observed the timing of surveillance. This pooling was done as a Table 3.1. The 
frequencies of independent variables of interest show that the majority of the patients had 




       Regarding the largest size of adenomas found, about 15.6% and 4.6 % of patients had 
≤ 5 mm and ≥ 10 mm adenoma found (Table 3.9).  Moreover, there were most of the 
patients with the largest adenoma had it in the right colon (12.5%). The distribution is 
similar for adenomas found in the left colon, rectum, and sigmoid colon (3.5%, 3.9%, and 
4.7%, respectively) (Table 3.10). Several polyp features were also identified at the initial 
colonoscopy. There were 454 of patients had any adenoma with tubulovillous/villous 
(2.7%), 3,826 tubular (22.7%), and 149 high-grade dysplasia (0.9%) features at initial 
colonoscopy (Table 3.11).      
        Overall, these preliminary reviews of the sample distributions guided our scheme for 
recoding variables and the models used to address our research questions. 
3.6.4 Potential limitations 
         Overall, our study has some potential limitations relative to our data characteristics. 
Our findings may not generalize to the US because we use data comes from a single 
endoscopy center in SC. Moreover, the retrospective study design may result in some loss 
to follow-up because some patients will have surveillance colonoscopies at other 
facilities. Another potential limitation is that the pathology report may not have clearly 
identified the number of polyps with different histology because multiple polyps were 
recorded within one colonic segment. Finally, our dataset does not document information 
on a family history of CRC or comorbiditites, which may drive surveillance colonoscopy 




 Table 3.5 Characteristics of the study population at baseline colonoscopy (n=16,897) 
  
All patients, N (%)    
(n=16,897) 








Race   
White 7,470(44.21%) 
Black 8,771(51.91%) 
Other/ Unknown 656(3.88%) 
Insurance status  
    Medicare 3,008(17.80%) 
    Medicaid 525(3.11%) 
    Private 11,939(70.66%) 
Uninsured 1,425(8.43%) 
Initial procedure timing   
Pre-2006 period 9,526(56.38%) 
2006 and later 7,371(43.62%) 
 
 
Table 3.6 Utilization of second colonoscopy by polyp status at initial colonoscopy 
(n=16,897) 
  Surveillance colonoscopy 
 Total, N (%) Yes, N (%) 
(N=4,016) 
No, N (%) 
(N=12,881) 
Advanced adenoma 1,683(9.96%) 900(53.48%) 783(46.52%) 
Non-advanced 
adenoma 
2,551(15.10%) 1,295(50.76%) 1,256(49.24%) 
Hyperplastic polyp or 
normal tissue 
5,654(33.46%) 1,045(18.48%) 4,609(81.52%) 
No polyp 6,917(40.94%) 748(10.81%) 6,169(89.19%) 
Missing
*
 92(0.54%) 28(30.43%) 64(69.57%) 
*




















< 1-year (n=757) 
 







































for overuse 1,793 - - - 
- 
10-year rescreening - - - - 10,778 
*
92 missing are without histology information for that polyp. We excluded 1,569 patients 
no 2
nd
 procedure due to not completing recommended surveillance interval, including 0 
for ≤ 1-year, 3 for 1-year, 556 for 3-year, and 1,010 for 5-year follow-ups. 
 
Table 3.8 Number of adenomas found in the same colonic segment at initial colonoscopy 
 N (%) 
No polyp 6,917 (40.94%) 
Hyperplastic polyp or normal tissue 5,654 (33.46%) 
1-2 adenomas 2,249 (13.31%) 
3-6 adenomas 1,656 (9.80%) 
≥ 7 adenomas 283 (1.67%) 
Missing 138 (0.82%) 
 
Table 3.9 The largest size of adenoma found at baseline colonoscopy 
 N (%) 
No polyp 6,917 (40.94%) 
Hyperplastic polyp or normal tissue 5,654 (33.46%) 
≤5mm 2,635 (15.60%) 
5.1-9.9mm 774 (4.58%) 
≥10mm 768 (4.55%) 










Table 3.10 The location where the largest adenoma found at baseline colonoscopy 
 N (%) 
No polyp 6,917 (40.94%) 
Hyperplastic polyp or normal tissue 5,654 (33.46%) 
Right 2,107 (12.47%) 
Left 589 (3.49%) 
Rectum 651 (3.85%) 
Sigmoid 793 (4.69%) 
Missing 186 (1.10%) 
 
Table 3.11 Frequency of patients with any adenoma showing the features of 
(1)Tubulovillous/villous adenomas, (2)tubular adenomas, and (3) high-grade dysplasia 
features at baseline colonoscopy
*
  (Total patients= 16,897; No polyp=6,917; Hyperplastic 
polyp=5,654; Adenomatous polyp=4,234)  
 Tubulovillous/villous 
adenomas, 
 N (%) 
Tubular adenomas, 
N (%) 
High-grade dysplasia,  
N (%) 
No 3,780(22.37%) 408(2.41%) 4,085(24.18%) 
Yes 454 (2.69%) 3,826 (22.65%) 149 (0.88%) 
Missing 92 (0.54%) 92 (0.54%) 92 0.54%) 
*












AN ASSESSMENT OF COMPLIANCE WITH SURVEILLANCE 
GUIDELINES ISSUED BY PROFESSIONAL SOCIETIES, AND 
IMPLICATIONS FOR RESOURCE UTILIZATION  
Abstract 
Background  
       Colorectal cancer (CRC) can be prevented by population-wide colonoscopy 
screening and polyp removal, followed by periodic surveillance of those with 
adenomatous polyps. Both overuse (premature) and underuse of colonoscopy 
(delayed/not done) are documented. Underuse may undermine CRC prevention while 
overuse causes inefficient use of provider workforce and reduced system screening 
capacity. We examined the impact of the 2006 U.S. Multi-Society Task Force guidelines 
on surveillance timing. 
Methods 
      We studied the timing of surveillance colonoscopies in a community-based cohort of 
patients with a screening colonoscopy between September 2001 and February 2010 at a 
large endoscopy center in South Carolina, followed through February 2011. We 
compared patients with screening colonoscopy done in the pre- and post-2006 periods for 




 not done), classified by recommended surveillance interval category, using chi-square 
tests and Kaplan-Meier (KM) estimation with the log-rank test. 
Results 
        Of 16,897 study patients, 4,234 were found to have adenomatous polyps 
(surveillance-eligible), of whom 2,195 (51.8%) had a surveillance colonoscopy. 
Surveillance timing was inappropriate for 91.8% of patients, being similar in the pre-and 
post-guideline periods. Underuse was more likely among ≤1- and 3-year recommended 
surveillance groups (p<0.001), and overuse among 5-year recommended surveillance 
(p<0.001). Among those without adenomas at screening colonoscopy, 14.3% (1,793 of 
12,571 pre-period patients) had a premature second colonoscopy after a mean of 4.65 
years, vs. the recommended 10-yearly repeat colonoscopy.    
Conclusions 
       Premature repeat colonoscopies among low-risk patients who do not qualify for 
surveillance per guidelines, and premature surveillance colonoscopies in patients with 
low-risk polyps consume significant provider resources. Minimizing overuse will spare 
scarce provider time for surveillance of high-risk patients at appropriate time intervals 
which may improve population outcomes at no extra cost. Underuse among all risk 
categories of surveillance-eligible patients should be addressed.  
Keywords: Surveillance colonoscopy, time intervals, adenoma features, guideline date. 
Introduction 
      Colorectal cancer (CRC) is the third most common cancer in the United States, and 
the second leading cause of cancer death in men and women combined. In South Carolina 




(Siegel, Miller, & Jemal, 2016). Individuals with adenomatous polyps are at risk of 
recurrence (metachronous lesions), which may increase the likelihood of cancer. 
Screening colonoscopies followed by periodic surveillance is recommended by the joint 
guidelines issued by the US Multi-Society Task Force on Colorectal Cancer (USMSTF) 
and the American Cancer Society (Winawer et al., 2006).  
      Surveillance guidelines have changed significantly since 1997, a summary of which is 
provided in Table 4.1. In 1997, 3-year surveillance was recommended for patients with 
large (>10mm) or multiple adenomas, and no specific guidelines were given for those 
with lower-risk adenomas (Winawer et al., 2006). There was no mention of person 
without adenomas or those with only hyperplastic polyps. The guidelines became more 
specific for the lower risk group (persons with 1-2 small, tubular adenomas) in 2003, 
recommending surveillance colonoscopy at 5 years rather than 3 years for this group 
(Winawer et al., 2003). In addition, the guidelines cautioned that evidence was still 
evolving, and that the interval could be changed with new evidence. The surveillance 
recommendations keep updated in the joint guidelines issued in 2006, which remains 
valid to date.  The increased and lower risk groups were definitively recommended for 3-
year and 5-year surveillance with an expectation that such definitive risk stratification 
would reduce the intensity of surveillance procedures in a substantial proportion of 
patients (Winawer et al., 2006). In the US, an estimated 25% of all colonoscopies were 
performed for surveillance purposes (Lieberman et al., 2000; Lieberman et al., 2005).  
       Both overuse (or premature) and underuse (or delayed/not done) of surveillance are 
reported, underuse among high-risk adults and overuse among low-risk adults (Cooper et 




payer health system, less than 25% of patients with adenomas received appropriately 
timed surveillance as per the Netherlands guidelines (van Heijningen et al., 2015). They 
also assessed the influence of a change in the Netherland’s guidelines issued in 2002. 
They found that was consistent with the recommendation in 24% of before the guideline 
date, vs. 11% of after the guideline date. The practice changed in favor of overuse after 
the guideline, while the percentage with underuse remained similar. Underuse threatens 
CRC prevention, while overuse causes inefficient use of colonoscopy resources and 
reduced screening capacity.  
       Few studies have evaluated actual adherence to the surveillance guidelines in the US 
on a large enough scale to identify patterns stratified by risk group, based on community-
based patient cohorts. The documented studies are based on self-reported patient surveys 
(Schoen et al., 2010), small sample sizes (Schreuders et al., 2013), academic medical 
center data (Kahn et al., 2015), and nation-wide histopathology registry data from other 
countries (the Netherlands) (van Heijningen et al., 2015). One study on surveillance 
compliance with guidelines was based on physicians’ self-reported practices in a survey 
(Mysliwiec et al., 2004). All studies have excluded persons without adenomas (low risk 
population not recommended for surveillance), except for two studies (Menees et al., 
2014; Schoen et al., 2010).    
       This study evaluated adherence to the 2006 USMSTF-ACS joint guidelines in a 
community-based screening cohort stratified by risk, and including surveillance-
ineligible patients. We used data from a community endoscopy center in South Carolina, 




document the surveillance practice before the 2006 guidelines and evaluate whether the 
guidelines resulted in surveillance practice changes to confirm to guideline. 
Methods 
      We used data from a licensed ambulatory surgery center for endoscopy in Columbia, 
South Carolina. The center is largely focused on providing screening and surveillance 
colonoscopies to average risk persons. Specifically, patients with inflammatory bowel 
disease, prior cancer history, or syndromic, inherited colorectal cancers are not served at 
the center. We obtained patient, procedure, and polyp data from the center’s databases 
populated by the center staff from patient charts. The center trains primary care 
physicians’ (PCPs) in colonoscopy using the gastroenterology fellowship training 
protocol used in academic medical centers for credentialing in colonoscopy. Training 
includes simulation on a mannequin followed by hands-on training by an endoscopy-
credentialed expert for the first 140 procedures. Post-training, performance quality and 
patient safety are ensured through a clinical performance protocol and technical support 
mechanisms that are designed to compensate for PCPs’ lack of formal gastroenterology 
training. The center’s polyp detection-maximizing clinical protocol involves a two-person 
engagement in the procedure, required to be used by all trained PCPs. PCPs are 
credentialed to perform procedures at the center with an expert available on-site for back-
up or rescue assistance (Xirasagar et al., 2015).  
Study design 
       This is a retrospective cohort study to evaluate the timing of surveillance 
colonoscopy based on findings at initial examination. The study period was September 4, 




colonoscopies were provided to 20,912 patients during the study period. We excluded 
997 procedures that were the third or higher colonoscopy for the index patient. We 
combined data on second procedures performed within 6 months of the first into the first 
procedure data, as those are make-up colonoscopies for sub-optimal completion of the 
first procedure, e.g. poor bowel preparation. The exception to this rule was a surveillance 
colonoscopy within 6 months recommended for specific risk individuals described below.  
      The 2006 surveillance guidelines recommend surveillance 2-6 months following the 
initial examination for patients with sessile adenomas that were removed piecemeal. We 
identified piecemeal removal by a variable “Destroyed=no” in the polyp dataset. The 
guidelines recommend 1-year surveillance for patients with hyperplastic polyposis 
syndrome or > 10 adenomas; 3-year surveillance for patients with 3-10 adenomas, ≥ 1 cm 
adenoma, or any adenoma with villous or tubulovillous features, or high-grade dysplasia; 
and, 5-year surveillance for patients with 1 or 2 small (<1cm) tubular adenomas or any 
adenoma without advanced features. No surveillance is recommended for patients 
without adenomatous polyps or less than 3 small hyperplastic polyps, only rescreening 
after 10 years. Based on these timing criteria, we excluded patients without a second 
procedure who had not completed the recommended surveillance interval during the 
study period (n=1,569). The final study sample consisted of 16,897 eligible study patients 
with a screening colonoscopy.  
Measures 
      Time interval to surveillance colonoscopy was the main outcome measure. Patients 
without adenomatous polyps or less than 3 small hyperplastic polyps were defined as not 




guidelines (S. J. Winawer et al., 2006). Timing was classified as appropriate if the 
surveillance was within 3 months before or after the recommended due date for the ≤ 1-
year surveillance group, and within 6 months before or after the due date for the ≥ 2-year 
surveillance group (van Heijningen et al., 2015). Early surveillance before the 3- or 6- 
month window was overuse (premature, before due), and delayed beyond the window 
was underuse (delayed, or not done). Table 4.2 summarizes the 2006 guidelines 
recommending surveillance at five different intervals: <1-year, 1-year, 3-year, and 5-year 
surveillance, and 10-year rescreening. The table also shows the operational definitions 
used in the study. For patients with multiple polyps, the most severe polyp characteristic 
was used to determine the surveillance interval category. Pre-guideline screening 
colonoscopies were those done in 2005 or earlier, and the remaining was classified as 
post-guideline patients.   
      All patients, pre- and post-guideline patients were evaluated for surveillance finding 
against the 2006 recommendations. Because the purpose was to evaluate provider 
practice changes once clear guidelines was issued, the 2006 recommended surveillance 
timings was used to assign a patient to overuse, underuse, and appropriate use category. 
Statistical analysis 
      Kaplan-Meier (KM) curves were used to estimate the cumulative probability of 
surveillance procedures over time following the screening colonoscopy. Patients were 
stratified into pre- and post- 2006 periods, and observed for the second procedure timing 
since the initial colonoscopy. The event of interest was having the second procedure 




      Study group differences were assessed using chi-square, Fisher’s exact test, and 
ANOVA test with a p-value of 0.05 for statistical significance. The log-rank test was 
used to compare KM curves of the pre- and post-2006 cohorts on the time-related 
probability of surveillance colonoscopy. SAS Version 9.4 statistical software was used 
for all analyses. The study was approved by the University of South Carolina Institutional 
Review Board.   
Results 
Study sample characteristics      
      Of study-eligible procedures, 20,912 were first (screening) procedures and 4,359 
were second procedures. Of 20,912 patients, we excluded patients aged below 40 years 
and more than 74 years (n=2,343), and cancer detected at first procedure (n=103).    
There were 9,526 patients with initial colonoscopy in the pre-guideline period (2005 or 
earlier) and 7,371 in the post-guideline period, 2006 and later (Figure 4.1). We classified 
patients screened in 2006 into the post guideline group because the earliest possible 
surveillance would have been due in the post guideline period (2007 or later) and could 
have complied with the guideline.  
       A total of 16,897 patients were included in the study. The mean follow-up period 
was 7.25 (SD, 1.22) years for the pre-guideline cohort and 2.85 (SD, 1.43) years for the 
post-guideline cohort. The majority were: female (54.1%), aged ≥ 50 years (83.7%), and 
Black (51.9%).  Of total screened patients, 4,234 were surveillance-eligible (i.e., had 
adenomatous polyps). Of them 2,195 (51.8%) completed a surveillance colonoscopy, 
1,635 pre-guideline patients and 560 post-guideline patients. Among those without 




second colonoscopy after a mean of 4.65 years. Of the total cohort, 4.8%, 11.2% and 
9.1%, were eligible for surveillance at ≤ 1 year, 3 years and 5 years, respectively, and 
74.4% were not eligible for surveillance (Table 4.3).  
Timeliness of surveillance in the pre- and post-guideline periods 
      The mean surveillance interval was 2.52 years among surveillance-eligible patients 
who completed the procedure,   2.71 years (SD, 1.22) and 1.95 years (SD, 0.99) for the 
pre- and post- guideline cohorts, respectively (p<0.001). Among patients who did not 
qualify for surveillance and had a premature second colonoscopy, their mean interval was 
4.82 years (SD, 1.27) and 2.35 years (SD, 1.22) in the pre- and post- periods, respectively 
(p<0.001).  
      Kaplan-Meier analysis showed that post-guideline patients had, on average, earlier 
surveillance compared to the pre-2006 cohorts among the 5-year recommended 
surveillance group (p<0.001). Among the no-surveillance recommended group, pre-
guideline patients had a higher probability of premature second colonoscopy than post-
guideline patients (p<0.001). There was no difference in surveillance timing of the pre- 
and post-guideline cohort among the ≤1-year and 3-year surveillance groups. The 
Kaplan-Meier surveillance probability curves are shown in Figures 4.2a, b, c, d.  
      Overall, surveillance timing was inappropriate for 91.8% of patients, similar in the 
pre-and post-guideline periods, with 2.8%, 14.9%, and 2.8% of patients recommended for 
≤ 1-year, 3-year, and 5-year follow-ups, receiving appropriately timed surveillance. 
Delayed or no surveillance occurred for 96.8% and 54.0% of ≤ 1-year and 3-year 
recommended surveillance groups. By contrast, among the 5-year recommended group, 




Among patients without adenomas at screening, 1,793 of 12,571(14.3%) patients had a 
premature second colonoscopy, 25.7% of pre-guideline patients, and 2.0% of post-
guideline patients (p<0.001) (Table 4.4). 
Discussion 
      The study found a high rate of deviation (91%) from the 2006 guidelines in a 
community-based cohort in South Carolina. About 50% of the cohort did not complete 
surveillance within the study period, which is concerning because of the risk of adenoma 
recurrence and cancer over their lifetime (Laiyemo et al., 2009; Morelli et al., 2013; 
Pinsky et al., 2009; Robertson et al., 2009). However, one study limitation is the 
possibility that some of these patients may have undergone surveillance with a different 
provider and therefore were not captured by the study. 
       Among ≤ 1-year and 3-year surveillance recommended groups, delay was the most 
common finding (96.8% and 54.0%, respectively). However, 48.7% and 51.1% had 
completed surveillance by the end of study period. Overuse (premature) surveillance was 
high among the 5-year surveillance groups (49.8% of patients). Overuse was higher in the 
post-2006 period (61.4%). Our findings are consistent with another community-based 
cohort study, high-risk patients with advanced adenomas (Schoen et al., 2010). The 
surveillance timeline adherence rate of 15.8% among the surveillance-eligible is lower 
than the rates reported in Canada (33%) and the Netherlands (21%) (Schreuders et al., 
2013; van Heijningen et al., 2015).  Both countries have single-payer health systems and 
nation-wide, integrated claims or registry databases.  In the Netherlands, 63.5% of 
surveillance-eligible patients completed surveillance; of whom 21% adhered to the 




and, among them, 15.8% timeline adherence. The Netherlands guidelines recommend 6-
year surveillance for patients with one or two adenomas, one year later than the 2006 US 
guidelines (Snel & de Wolf, 1988). Both the Canadian and Netherlands studies did not 
assess second procedures among patients who do not qualify for surveillance due to lack 
of adenomas at screening. In the US, a Medicare claims study documented a second 
procedure rate of 61.3% over 5-years among patients with a polypectomy aged over 70 
years (histology not known) or having a family history of gastrointestinal neoplasm 
(Cooper et al., 2013).   
      A recent study examined provider adherence to the 2012 USMSTF guidelines in the 
physician’s follow-up notes recommending surveillance (Kahn et al., 2015).  This study 
used data on a 2011-2013 cohort from an academic medical center and reported that 
providers recommended surveillance as per the guidelines for 77.4% of patients in the 
follow-up notes (Kahn et al., 2015).  
        Delayed colonoscopy is reasonable and anticipated among ≤ 1-year and 3-year 
surveillance groups because the recommended intervals are short. Possible reasons for 
delay may be procrastination due to the patient’s experience of discomfort or dislike of 
the bowel prep process, or a busy personal schedule (Jones, Devers, Kuzel, & Woolf, 
2010; Jones, Woolf, et al., 2010; Medina, McQueen, Greisinger, Bartholomew, & Vernon, 
2012). Our finding of overuse (premature surveillance) among the 5-year group in the 
post-guideline period, may be due to providers being cautious and defaulting to the 
earliest 1997 guidelines (3-year surveillance for patients with large or multiple adenomas, 
no recommendation for patients with small adenomas or other advanced histology 




et al., 1997; Winawer et al., 2006). In the 2003 guidelines, high-grade dysplasia is not 
mentioned as a surveillance criterion, and a tentative recommendation was made for 5-
yearly surveillance for patients with 1-2 small adenomas (Table 4.1). These factors, 
together with the fast-changing adenoma risk perceptions published during the study 
period may have contributed to the heightened, post-2006 overuse of colonoscopy among 
the 5-year surveillance group.  
     Studies have documented providers’ lack of knowledge of guideline revisions, and a 
preference for a cautious interpretation of the research evidence used to support the 
revised recommendations (Imperiale, 2011; Kruse et al., 2015; Saini et al., 2009). A 
recent survey assessed gastroenterologists’ opinions about the 2006 guidelines and the 
factors driving their own follow-up recommendations. It found that 11% of 
gastroenterologists felt that the guidelines were not adequate to prevent cancer (Patel, 
Tong, Ahn, Singal, & Gupta, 2015). Some authors have supported shorter surveillance 
intervals because of potentially missed adenomas at screening colonoscopy (Kim et al., 
2012; Nakao et al., 2013). Increasing CRC risk with age, particularly the high risk 
beyond 70 years of age may heighten this concern and contribute to early surveillance 
(Goodwin et al., 2011; Imperiale, 2011). These factors may explain the significant 
overuse observed in our study. To address providers’ lack of knowledge of the guidelines, 
it has been suggested that electronic medical record (EMR) systems may provide a 
solution, by triggering automated reminders to patients and providers when follow-up is 
due (Leffler et al., 2011). Increasing patients’ awareness of the significance of their 





        An important finding is that 14.3% of patients without adenomas at screening 
colonoscopy had a premature second colonoscopy after a mean period of 4.65 years. Of 
those, 37.1% (665 out of 1,793) had hyperplastic polyps, mostly small, in the left colon, 
and less than three in number. The distribution of these patients by pathology findings at 
screening is shown in Table 4.5.  A family history of CRC and bowel symptoms could 
have caused these premature second procedures. However our data lack this information 
that could explain part of the overuse.  
      There are few studies on the rate of premature second screening colonoscopies in the 
US. A Veterans Administration study of physicians’ notes reported that about 9.2 % of 
patients with 1 to 2 small (<1cm) non-adenomatous polyps were recommended for a 
second colonoscopy before the recommended 10-year interval (Menees et al., 2014). 
Because bowel symptoms may prompt a colonoscopy in this age group regardless of the 
originally planned follow-up schedule, the actual rate of second colonoscopies may be 
similar to the rate observed in our study.  
       Our study has several strengths. It is one of the few studies to evaluate changes in 
surveillance practice in a community-based practice setting in the United States following 
the issuance of definitive guidelines. Despite 74.4% (12,571 of 16,897 patients) not 
qualifying for surveillance, 14.3% of them had a premature second procedure. This 
contributes a large volume of procedures that may occupy provider time with minimal 
cancer-reducing value. Another strength of our study is the availability of data on the 
total number of adenomatous polyps, including numbers found within a colonic segment 
that are typically sent for histology in a single jar. This data field resulted in re-




group (16.8% of the surveillance-eligible sample). Most prior studies of adenoma 
characteristics base the number of adenomas on a count of the polyp jars, which is the 
data typically found in claims data or the Clinical Outcomes Research Initiative (CORI) 
database that is the most widely reported dataset in colonoscopy studies (D. A. 
Lieberman et al., 2008). 
      Our study has several limitations. Our findings may not generalize to the US 
population or other endoscopy centers because we used data from one center. The 
retrospective study design also entails some loss to follow-up because some patients may 
have undergone surveillance colonoscopy at other facilities. However, the center’s 
surveillance completion rate of 51.8% is close to the Netherlands’ population-based rate 
of 63.5%, and the rate of 61.3% among Medicare beneficiaries with a polypectomy in the 
US. Additionally, the study center has a surveillance colonoscopy proportion of 23.8% of 
all colonoscopies, compared to 25%, nationally, documented in the US (Lieberman et al., 
2000; Lieberman et al., 2005). These similarities may suggest that the observed 
surveillance completion rate at the center may be close to the true surveillance 
completion of the cohort.   
      Another limitation is that because of study period constraints we have shorter follow-
up for post-guideline patients, which may misclassify some of the tardy surveillance 
cases as not completed, if they completed it after the study period. Finally, our data lack 
family history data and symptomatology data which may account for part of the early 
surveillance or premature second screening cases (Schoen et al., 2010). Approximately 
11.2% of the population aged 45-70 years has at least one first-degree relative with CRC 




       In conclusion, less than 10% of surveillance-eligible patients received timely 
surveillance. Less than 50% surveillance rate (after counting tardy surveillance) among 
high-risk patients (recommended ≤1- or 3-year surveillance) indicates that active follow-
up among these patients should be a priority. To accommodate the increased load due to 
needed surveillance cases, the current pattern of overuse among the 5-year surveillance 
group and no-surveillance recommended group should be addressed. Minimizing overuse 
will spare scarce provider time for surveillance of high-risk patients at appropriate time 





















Excluded patients (n=4,015): 
2,343 aged < 40 or ≥ 75 years  
103 with carcinoma 
1,569 patient no 2nd procedure due to not  





Screening done Pre-2006  
9,526 
Screening done Post-2006  
7,371 































Figure 4.1 Study-eligible patients with a screening colonoscopy, and use of 
second procedure, pre- and post-2006 guidelines.*92 patients without polyp 













Figure 4.2a Cumulative probability of surveillance colonoscopy among the ≤1-
year surveillance recommended group (pre vs. Post guideline) (P=0.778) 
Figure 4.2b Cumulative probability of surveillance colonoscopy among the 3-









Figure 4.2c Cumulative probability of surveillance colonoscopy among the 5-
year surveillance recommended group (pre vs. Post guideline) (P<0.001) 
Figure 4.2d Cumulative probability of surveillance colonoscopy among the no-




Table 4.1 Details of the 1997, 2003, and 2006 surveillance guidelines recommendations  
 Surveillance interval 
recommendation 
1997 recommendations  
    Large (≥1cm), multiple adenomas 3 years 
    Lower-risk adenomas (1-2 small adenoma,<1cm) No specific guidelines 
    High-grade dysplasia or villous features No specific guidelines 
2003 recommendations  
Numerous adenomas, a malignant adenoma (with  
invasive cancer), a large sessile adenoma 
A short interval (based on 
clinical judgment) 
    Large (≥1cm), villous adenoma, ≥3 adenomas 3 years 
    1-2 small (<1 cm) tubular adenomas 5 years (but noted that 
change in light of evidence 
is evolving) 
   High-grade dysplasia  No specific guidelines 
2006 recommendations  
  Sessile adenomas that are removed piecemeal 2-6 months 
  a) Hyperplastic polyposis syndrome
*
 
  b) >10 adenomas 
1 years 
  a) 3-10 adenomas 
  b) adenoma ≥1 cm  
  c) any adenoma with villous features or high-grade    
      dysplasia 
3 years 
  a) 1 or 2 small (<1 cm) tubular adenomas with low-grade  
      dysplasia 
  b) Any adenoma without advanced features 
5 years 
  a) Small (<1 cm) rectal hyperplastic polyps 
  b) Normal tissues (include few hyperplastic polyps or no   




Hyperplastic polyposis is defined as: (1) at least 5 histologically diagnosed hyperplastic polyps proximal 
to the sigmoid colon, of which 2 are greater than 1cm in diameter, or (2) any number of hyperplastic polyps 
occurring proximal to the sigmoid colon in an individual who has a first-degree relative with hyperplastic 
polyposis, or (3) more than 30 hyperplastic polyps of any size distributed throughout the colon. Since our 
study does not have data on first-degree relatives, we included the first and third criteria to define 















Table 4.2 Operational definitions used for classifying surveillance colonoscopy as 
appropriate, overuse, and underuse 
* 
 Surveillance interval 
recommendation  
(in years) 
Operational study definitions of 
appropriate timing 
(in years) 
Polyp types   
1) Small (<1 cm) rectal 
hyperplastic polyps 
2) Normal tissues  
(include few hyperplastic 




  Surveillance timelines category  
(time interval in years) 
1) 1 or 2 small (<1 cm) 
tubular adenomas with 
low-grade dysplasia,  





1) 3-10 adenomas,  
2) adenoma ≥1 cm,  
3) any adenoma with 













Sessile adenomas that are 
removed piecemeal 








Hyperplastic polyposis is defined as: (1) at least 5 histologically diagnosed hyperplastic polyps proximal 
to the sigmoid colon, of which 2 are greater than 1cm in diameter, or (2) any number of hyperplastic polyps 
occurring proximal to the sigmoid colon in an individual who has a first-degree relative with hyperplastic 
polyposis, or (3) more than 30 hyperplastic polyps of any size distributed throughout the colon. Since our 
study does not have data on first-degree relatives, we included the first and third criteria to define 













Table 4.3 Study population at screening colonoscopy, classified by date of screening 
colonoscopy, pre- or post-guideline (n=16,897)
 **
 








2006 and later       
(n=7,371) 
Patient characteristics      
Gender
*
      
Male 7,673(45.4%) 4,304(45.2%) 3,369(45.7%) 
Female 9,144(54.1%) 5,143(54.0%) 4,001(54.3%) 
Missing 80(0.5%) 79(0.8%) 1(0.0%) 
Age(years)
*
      
40-49 2,755(16.3%) 1,447(15.2%) 1,308(17.8%) 
50-59 8,367(49.5%) 4,642(48.7%) 3,725(50.5%) 
60-74 5,775(34.2%) 3,437(36.1%) 2,338(31.7%) 
Race
*
      
White 7,470(44.2%) 4,166(43.7%) 3,304(44.8%) 
Black 8,771(51.9%) 4,829(55.1%) 3,942(44.9%) 
Other or unknown 656(3.9%) 531(5.6%) 125(1.7%) 
Insurance status
*
      
Medicaid 525(3.1%) 322(3.4%) 203(2.8%) 
Medicare 3,008(17.8%) 1,750(18.4%) 1,258(17.1%) 
Private  11,939(70.7%) 6,238(65.5%) 5,701(77.3%) 
Uninsured 1,425(8.4%) 1,216(12.8%) 209(2.8%) 
Recommended surveillance interval
*
      
<1-year surveillance 757(4.5%) 523(5.5%) 234(3.2%) 
1-year surveillance 54(0.3%) 23(0.2%) 31(0.4%) 
3-year surveillance 1,891(11.2%) 1,132(11.9%) 759(10.3%) 
5-year surveillance 1,532(9.1%) 1,291(13.6%) 241(3.3%) 
No surveillance recommended 
(10-year rescreening only) 
 
12,571(74.4%) 6,492(68.2%) 6,079(82.5%) 
Missing 92(0.5%) 65(0.7%) 27(0.4%) 
Mean person year of observation 5.33(2.55) 7.25(1.22) 2.85(1.43) 
*
P<0.05 for tests of difference between guideline date and characteristics of study population, using Chi-
square tests. 
**
Mean screening follow-up was 7.25 years for pre-guideline group (range,5.11-9.44; SD,1.22) and 2.85 








Table 4.4 Timing of surveillance colonoscopy relative to the 2006 recommended surveillance intervals among the pre-guideline and 
post-guideline cohorts (pre- vs. post- guidelines)
 
Recommended surveillance 








(Delayed relative to 
recommendation)                         
Not done 
(by end of 




Total all surveillance groups 
(n=4,234)
 *
 1,355(32.0%) 347(8.2%) 493(11.6%) 2,039(48.2%)  
Total Pre-2006(n=1,291) 970(32.7%) 255(8.6%) 410(13.8%) 1,334(44.9%)  
Total Post-2006(n=241) 385(30.4%) 92(7.3%) 83(6.6%) 705(55.7%)  
Total ≤ 1-year surveillance 
(n=811)
 *
 3(0.4%) 23(2.8%) 369(45.5%) 416(51.3%) - 
    Pre-2006 (n=546) 2(0.4%) 9(1.7%) 297(54.4%) 238(43.6%) - 
    Post-2006 (n=265) 1(0.4%) 14(5.3%) 72(27.2%) 178(67.2%) - 
Total 3-year surveillance 
(n=1,891)
 *
 589(31.2%) 281(14.9%) 97(5.1%) 924(48.9%) - 
    Pre-2006 (n=1,132) 353(31.2%) 203(17.9%) 86(7.6%) 490(43.3%) - 
    Post-2006(n=759) 236(31.1%) 78(10.3%) 11(1.5%) 434(57.2%) - 
Total 5-year surveillance 
(n=1,532)
 *
 763(49.8%) 43(2.8%) 27(1.8%) 699(45.6%) - 
    Pre-2006(n=1,291) 615(47.6%) 43(3.3%) 27(2.1%) 606(46.9%) - 
    Post-2006(n=241) 148(61.4%) 0 0 93(38.6%) - 
Total 10-year rescreening 
group(No need for surveillance) 
(n=12,571)
 *
 1,793(14.3%) - - - 10,778(85.7%) 
   Pre-2006 (n=6,492), Mean  
   follow-up period=7.27 (1.25) 1,671(25.7%) - - - 4,821(74.3%) 
   Post-2006(n=6,079) , Mean  
   follow-up period=2.70 (1.44) 122(2.0%) - - - 5,957(98.0%) 
*





PATIENT VARIABLES AND PROFESSIONAL SOCIETY 
GUIDELINES DRIVING THE TIMING OF SURVEILLANCE 




      Well-performed colonoscopy can prevent colorectal cancer (CRC). Because of the 
higher risk of adenoma recurrence or CRC, surveillance colonoscopy is recommended in 
all patients with a history of high-risk polyps. The factors driving the actual patterns of 
surveillance use remain unclear. Understanding the extent to which individual risk factors 
influence surveillance compliance and the timing decision is important to improve 
adherence and reduce cancer incidence.  
Methods 
      This is a retrospective, cohort study of patients with a screening colonoscopy at a 
community-based endoscopy center between September, 4, 2001 and February, 11, 2010, 
observed through February 2011. Surveillance overuse (premature) and underuse 
(delayed or not done) were defined based on surveillance completion earlier, or later than 




risk2006 guidelines). We used logistic and linear regression modeling to identify the 
patient, polyp and procedure factors associated with surveillance timing, including 
possible risk factors not specified in the guideline in making the recommendations.  
Results 
      Of 16,805 study-eligible patients, majority were female (54.1%), aged 50-59 years 
(48.5%), Black (51.9%), and had Medicare or private insurance (88.5%). Of 4,234 
surveillance-eligible patients, 2,195 patients (51.8%) had a surveillance colonoscopy. 
Only 8.2% (347 of 4,234) surveillance-eligible patients were compliant with guideline-
recommended timing. Adjusted analysis showed that overuse was more likely among the 
5-year surveillance group (OR: 14.39; 95%CI: 10.03-20.64) relative to the ≤3-year 
surveillance group. Other significant factors predicting overuse were having a large 
adenoma (OR: 1.81; 95%CI: 1.25-2.63), having multiple advanced adenoma 
characteristics (OR: 2.26; 95%CI: 1.30-3.93), and post-guideline period (OR: 1.73; 
95%CI: 1.30-2.31). Delayed surveillance was more likely among patients with the largest 
adenoma found in the right colon (OR: 1.49; 95%CI: 1.12-1.98) and Medicaid 
beneficiaries (OR: 3.22; 95%CI: 1.14-9.09). Within the ≤3-year surveillance group, 
patients with adenomas larger than 5 mm, or multiple advanced characteristics were more 
likely to have early surveillance. Among those not eligible for surveillance, premature re-
screening (before 10 years) was associated with having a non-adenomatous polyp (vs. no 
polyp) and higher age. 
Conclusions 
     Contrary to expectations, surveillance overuse increased following the issuance of 




colonoscopy. The findings suggest that concerns about individual patients’ cancer risk 
beyond the criteria used in surveillance guidelines may underlie many decisions of 
premature surveillance. Lack of family history data is a study limitation, which could 
account for part of the premature surveillance cases. Significant underuse among 
Medicaid beneficiaries exists, and should be explored to identify the barriers to 
surveillance in this group.  
Keywords: Surveillance colonoscopy, polyp features, insurance status, initial procedure 
year. 
Introduction 
       Colorectal cancer (CRC) is the third leading cancer in the United States, with nearly 
50,000 deaths in 2015 (ACS, 2015). In South Carolina, an estimated 2,220 new cases and 
830 deaths are expected in 2016 (Siegel et al., 2016). Well-performed screening 
colonoscopies help prevent cancer through visualization of the entire colonic surface and 
removal of precancerous polyps (adenomas) (Winawer et al., 1993; Xirasagar et al., 2015; 
Zauber et al., 2012). Screening colonoscopy followed by colonoscopic surveillance for 
patients with adenomatous polyps is recommended, because of the risk of adenoma 
recurrence and cancer (Leung et al., 2010; Pinsky et al., 2009). Surveillance guidelines 
were updated by the U.S. Multi-Society Task Force (USMSTF) and American Cancer 
Society in 2006, which emphasized risk stratification by polyp features at screening 
colonoscopy in recommending surveillance intervals following screening colonoscopies 
(Winawer et al., 2006). 
       Although evidence supports that colonoscopic polypectomy can reduce cancer 




recommended intervals. The literature shows overuse of surveillance (too early) among 
low-risk adults and underuse (delayed) among high-risk adults (Schoen et al., 2010; Sint 
Nicolaas et al., 2013). The purpose of efforts to increase guideline concordance is to 
achieve higher adenoma detection, and to emphasize that overuse of surveillance does not 
increase cancer prevention (Sint Nicolaas et al., 2013). Understanding the factors driving 
overuse or underuse may help to identify patient groups at risk for inappropriate 
surveillance timing, and alert providers and patients about the risks of unnecessary 
colonoscopies or delaying surveillance. 
       Previous studies of surveillance have mostly examined pre-2006 cohort data 
(Lieberman et al., 2008; Lieberman et al., 2007; Martinez et al., 2009). Most studies did 
not account for patient and screening procedure characteristics that may influence 
physicians’ recommendations for follow-up procedures (Ko et al., 2010; Laiyemo et al., 
2010; Lieberman et al., 2008). Moreover, studies of surveillance practice compared to 
guidelines have used patient survey data with no data on polyp features (Saini et al., 
2009), small sample sizes (Kim et al., 2012), or cohorts from academic medical centers 
which may be more up-to-date with the latest practice guidelines (Kahn et al., 2015). 
There is little documentation on surveillance practices as compared to guideline 
recommendations at community-based endoscopy centers, and no literature on 
“surveillance” of patients who do not qualify for surveillance based on the professional 
society guidelines. 
      This study seeks to identify the patient-level factors associated with surveillance 
colonoscopy completion and timing, adjusting for the professional society guideline date. 




by the guideline issuing society in recommending the surveillance intervals, patient 
demographics, or procedure-related factors. We used data from a large cohort served at a 
community endoscopy center in South Carolina, which has a documented high rate of 
CRC prevention among its screened patients (Xirasagar et al., 2015).  
Methods 
Study population and sample selection 
        This is a retrospective cohort study of patients provided screening colonoscopy at a 
community-based endoscopy center between September 4, 2001, and February 11, 2010, 
observed through February 2011. The center mainly uses colonoscopy-trained primary 
care physicians (PCPs) who bring their screening-eligible, primary care patients for 
screening and surveillance colonoscopy at a licensed endoscopy center.  As a general 
policy, the center mainly focuses on screening colonoscopies of average-risk patients and 
their surveillance (those without inflammatory bowel disease, prior cancer history, or 
syndromic, inherited colorectal cancers). The center’s polyp detection-maximizing 
clinical protocol requires a 2-person technique, required to be used by all PCPs who 
perform procedures at the center, with an expert on site for back-up assistance (Xirasagar 
et al., 2015). 
       Polyp features at screening, patient demographics, and procedure-related 
characteristics were obtained from center’s administrative and medical databases. We 
reviewed a total of 26,523 screening and second procedure colonoscopies provided to 
20,912 patients during the study period. Third or higher order procedures provided to a 
patient were excluded (n=997). Further, we combined data from 225 second procedures 
performed within 6 months of the first procedure into the first procedure data because 




procedures, 20,912 were the screening procedure. Of those 20,912 patients, we excluded 
2,343 aged < 40 or ≥ 75 years, and 103 patients with cancer found at screening 
colonoscopy.  
        We adjusted for guideline date by classifying patients into a variable, guideline 
concordance. The variable categories were overuse, delayed, and not done relative to the 
recommended surveillance interval per the 2006 joint guidelines of the U.S Muti-Society 
Task Force (USMSTF) on Colorectal Cancer and the American Cancer Society (Winawer 
et al., 2006). The guidelines recommend surveillance examinations after <1-year, 1-year, 
3- years, and 5-years, depending on polyp characteristics at screening. Based on these 
timings, 1,569 patients who had not completed their recommended surveillance interval 
by the end of study period were excluded from study.  
Measures  
       We had three primary outcomes of interest: any second colonoscopy (yes/no), the 
timing of the second colonoscopy relative to the screening procedure (categorized into 
overuse, appropriate, late or not done), and time interval since screening (continuous 
variable, years). Consistent with a documented study, we defined guideline concordant 
surveillance if the procedure took place within a range of ±3 months from due date for 
the ≤ 1-year surveillance-recommended group, and ±6 months for >1 year surveillance 
group (van Heijningen et al. 2015). Overuse was surveillance earlier than the range, 
(premature relative to guideline), delayed (later than the range), and not done, as of the 
end of study period. 
         Polyp findings at screening colonoscopy, patient insurance status, and screening 




Patient adenoma status was defined by their most advanced adenoma at screening 
procedure (if they had more than one adenoma). Patients with advanced characteristics 
were those with ≥ 3 adenomas of any size, an adenoma with >25% villous features, 
adenoma of 1 cm or more, or high-grade dysplasia (Winawer & Zauber, 2002; Winawer 
et al., 2006). According to the 2006 guidelines, patients with advanced adenoma 
characteristics by histology and ≥3 adenomas are recommended surveillance at 3 years. 
We identified patients with 3 or more adenomas using two variables; we summed the 
polyp jars reported with adenoma histology, and identified those with 3 or more 
adenomas in the same colonic segment using another data field, Polyp quantity which is 
specified for each segment represented by a single polyp jar.  
We explored the potential role of adenoma features that are not assigned as high-risk 
adenomas meriting a specific surveillance recommendation. These were: location of the 
largest adenoma (right vs. left), number of colon anatomic locations found to have 
adenoma,(1-2 vs. 3-4 locations), the largest size of the patient’s adenomas (≤5mm, 5.1-
9.9mm, and ≥10mm), number of adenomas found in the same colonic segment (1-2 
adenomas and ≥ 3 adenomas), and presence of ≥ 2 advanced adenoma characteristics 
(yes/ no). Insurance was classified into Medicaid, Medicare or private, and uninsured. 
Finally, we defined patients based on their screening year, before 2006, pre-guideline, 
and 2006 or later, post-guideline.   
Statistical analysis 
       Multiple logistic and multinomial logistic regressions were performed to identify the 
factors associated with the likelihood of any second procedure, and of timely surveillance 




continuous variable (in years) with the patient, procedure, and polyp characteristics. SAS 
Version 9.4 was used for statistical analysis and a p-value < 0.05 was used. 
Results 
Patient characteristics 
         A total 16,805 patients with a screening colonoscopy were studied after excluding 
92 patients with missing histology. The demographic distribution of patients, screening 
period (pre- or post- guideline) and polyp characteristics at screening colonoscopy are 
presented in Table 5.1. Of the total sample, 4,234 (23.7%) were eligible for surveillance, 
and 2,195 (51.8%) had completed surveillance colonoscopy. Of 12,571 patients who 
were not eligible for surveillance, 1,793 (14.3%) had a premature second procedure 
(within 10 years). 
    Of the total sample, majority (54.1%) were female, Black (51.9%), and the largest age 
group (48.5%) was 50-59 years. Most had private or Medicare insurance (88.5%). The 
majority of the sample (56.3%) had their screening procedure in the pre-2006 period. Of 
surveillance-eligible patients, 48.7%, 51.1% and 54.4% of the 1-year, 3-year and 5-year 
surveillance groups had completed the second procedure (Table 5.2).  The mean follow-
up period was 5.3 years (±2.6), 7.25 years for the pre-guideline cohort (±1.2) and 2.85 
years for the post-guideline cohort (±1.4), not reported in the table. 
Adherence to recommendations among surveillance-eligible patients 
      Table 5.2 shows that overall, 8.2% (347 of 4,234) had appropriate timing of 
surveillance, 32.0% had overuse, 11.6% had delayed procedures, and 48.2% of 
surveillance-eligible patients did not complete it by the end of the study period. Overall 




surveillance had overuse (earlier than recommended surveillance). Table 5.2 also shows 
the demographic distribution of adherent and non-adhering patients. The mean 
surveillance interval was 2.37, 2.22, and 2.94 years among the ≤1-year, 3-year, and 5-
year surveillance groups, respectively (not shown in the tables). 
      Table 5.3 presents the adjusted likelihood of a second procedure among the sample. 
Older persons (aged over 50 years, ORs, 1.42,1.23), and Blacks (OR: 1.22; 95% CI: 1.07-
1.39) were more likely to complete the second procedure, as was the 5-year surveillance 
group (compared to the ≤1-year group, OR, 1.26, 95%CI 1.06-1.51), patients with 
multiple advanced adenoma characteristics (OR, 1.64; 95% CI, 1.28-2.11), undergone 
screening in the pre-guideline period (OR: 1.61), and those with private/Medicare 
insurance (OR 1.29 95%CI: 1.04-1.61). 
Predictors of earlier surveillance than recommended within risk categories    
       Analyses were done within each risk category represented by the recommended 
surveillance interval. Table 5.4 presents the associations of surveillance time interval 
(continuous variable) among those who completed surveillance. Post-guideline patients 
had, on average, 6-6.8 months earlier surveillance. Patients with adenomas larger than 
5mm, and those with multiple advanced adenoma characteristics were associated with 
earlier surveillance (2.8-7.8 months earlier, represented by coefficient estimates 0.23 and 
0.65 respectively).  
      Table 5.5 presents the results of adjusted analyses of overuse (early), delayed 
surveillance, and surveillance not done among the surveillance eligible. Factors driving 
overuse were post-guideline period, being in the 5-year surveillance group, larger 




delayed surveillance were Medicaid, and adenoma located in the right colon. Factors 
associated with not completing surveillance were post-guideline period, and being in the 
5-year surveillance group. 
      The odds of non-completion of surveillance (vs. completion) are shown in Table 5.6. 
Non-completion was less likely among those of younger age (50-59 years), Blacks, 
Medicare or private insurance, belonging to the 5-year surveillance group, and having 
multiple advanced adenoma characteristics, all consistent with the findings for overuse.  
Non-completion was more likely among post-guideline patients.  
Premature second procedure among those not eligible for surveillance  
       Table 5.7 shows the adjusted likelihood of a second procedure among those who 
were not eligible for surveillance. Older persons (aged over 50 years, ORs, 1.33-1.58), 
Blacks (OR: 1.59; 95% CI: 1.41-1.78), pre-guideline period (OR: 16.7), and having a 
polyp (hyperplastic or normal tissue, ORs, 2.03 and 2.47, respectively) were associated 
with increased likelihood of a second procedure. Of 1,793 persons who had a second 
procedure, 93.2 % were from the pre-guideline period, and 37.1 % (665 patients) had 
hyperplastic polyps (table not shown).   
Discussion 
      Our study found that 51.8% of surveillance-eligible patients had completed a 
surveillance procedure, although guideline-concordance of timing was very low (8.2%). 
The surveillance completion rate is similar to the documented rate of 53.9% among a 
National Cancer Institute - recruited community-based screening cohort of  the Prostate, 
Lung, Colorectal, and Ovarian (PLCO) cancer screening trial, followed up for a median 




2010). Within the risk sub-groups, our study found that 51.1% of the 3-year surveillance 
group and 54.4% of the 5-year surveillance group had completed surveillance, compared 
to 58.2% and 46.7% respectively among the PLCO study participants. The differences in 
rates are consistent with the shorter follow-up period in our study; this is supported by 
our finding that the post-guideline cohort had a lower adjusted likelihood of surveillance 
completion. The post-guideline cohort had a mean follow-up period of 2.9 years 
compared to 7.3 years for the pre-guideline cohort.   
Regarding  surveillance timing concordance, a Canadian academic medical center  
study reported a 33% rate of guideline timing concordance among 265 patients who 
completed surveillance (Schreuders et al., 2013). Comparatively our rate of guideline 
concordant timing among those who completed surveillance is 15.8% (347 out of 2,195 
patients).  A Netherlands study reported 21% timing concordance among 2,997 
surveillance-eligible patients in their national registry, compared to our corresponding 
rate of 8.2% (van Heijningen et al., 2015).  The US has a shorter recommended 
surveillance interval for persons with 1-2 adenomas (5 years) compared to the 
Netherlands (6 years). The Netherlands and Canada have a universal healthcare coverage 
system. Among patients with advanced adenomas, the Canadian study reported 29% 
completing surveillance on time, and the Netherlands reported 18%, compared to 29.1% 
in our study (281 out of 967) (Schreuders et al., 2013; van Heijningen et al., 2015). 
  The PLCO study of the US did not explore timing concordance with the guidelines. 
Our study adds to the literature by presents the timing concordance with guidelines in the 
US, and further, examined the role of specific polyp and patient characteristics that may 




compliance. We found that within each surveillance risk group, polyp characteristics that 
are not identified as risk criteria in the surveillance guidelines may be driving at least a 
part of the earlier-than-recommended surveillance.  Patients with larger adenoma sizes, 
and those with multiple advanced adenoma characteristics are receiving earlier than 
recommended surveillance, about 6 months earlier. These findings suggest that the 
practicing clinician may be considering the individual patient’s risk of developing cancer 
based on polyp features in tailoring the surveillance recommendation.  
  Our finding is also consistent with a recent study of physician recommendations for 
surveillance following screening at an academic medical center. They showed that 
patients with more than three adenomas were more likely to be recommended earlier than 
guideline-suggested surveillance (overuse) (Kahn et al., 2015). Our findings are also 
consistent with another study that reported increased overuse among patients with dual 
advanced features (co-existing high-grade dysplasia and large size) (Zhan et al., 2015).  A 
higher risk of adenoma recurrence or cancer among patients with advanced adenomas is 
documented by several authors (Laiyemo et al., 2008; Lieberman et al., 2007; Saini et al., 
2006).   
Our finding of overuse (early surveillance) among patients with 5-year recommended 
intervals (compared to 3-year) is consistent with other studies (Saini et al., 2006; 
Schreuders et al., 2013; van Heijningen et al., 2015). The high overuse rate among the 5-
year group, post-guideline (which changed the recommendation for this group from 3 
years to 5-years) may reflect a persistent effect of the 1997 guidelines. These guidelines 
recommended 3-year surveillance among patients with large (>10mm) or multiple 




1997). While the 2003 guidelines indicated a timing of 5 years for “lower-risk” patients 
(1-2 small tubular adenomas), it also emphasized that the evidence was still evolving and 
that the recommended interval could change with new evidence. Part of the 14.3% 
“surveillance” among the no-surveillance recommended group may be attributable to a 
family history of CRC (data not available) and the lack of definitive guidelines before 
2006. It should be noted that 93.2% of patients who underwent premature second 
procedures were screened before 2006.  
  Other authors have suggested that overuse may partly be driven by concerns about 
interval CRCs arising from lesions missed at screening colonoscopy, prompting earlier 
surveillance among patients with elevated risk status (Saini et al., 2009). Concurrent with 
overuse, underuse is also a problem, with 48.2% not completing surveillance. A new 
finding is that right colon adenomas are associated with delayed surveillance (compared 
to left-sided adenoma). This is contrary to the expected overuse for this group, they have 
a 2-fold risk of advanced neoplasia at surveillance (Laiyemo et al., 2008; Martinez et al., 
2009).  Notably, this finding appears to be confounded by race. When race was included 
in the model and anatomic location was excluded, Black race was associated with the 
same coefficient estimate as anatomic location. When both were included, the anatomic 
location showed significance and race lost significance. Because Blacks are more likely 
to have right-sided adenomas (Nouraie et al., 2010) and given the nearly 50% excess 
CRC mortality experienced by Blacks, our finding needs further study with a larger 
sample size and multi-center studies.   
   Medicaid was associated with delayed surveillance, which is consistent with studies 




worse CRC survival among Medicaid beneficiaries (Parikh, Robinson, Zaydfudim, 
Penson, & Whiteside, 2014; Shapiro et al., 2012; Ward et al., 2008). Our finding may 
support why late stage diagnosis and poorer survival is taking place among Medicaid 
beneficiaries. Further analysis of our data showed that Medicaid beneficiaries have a 
higher frequency of advanced adenoma than private insurance (11.8% vs. 9.2%, 
respectively, p<0.001), which may play into late-stage CRC diagnosis and poorer 
survival when combined with delayed surveillance.   
  An important new contribution is our reporting on “surveillance” among those not 
eligible for surveillance, with a 14.3% rate of second procedures that represent premature 
re-screening.  This needs further exploration in datasets with family history data. One 
study reported that 9.2 % of surveillance-ineligible patients were recommended by their 
physician for an early second procedure. No data was reported on completed second 
procedures (Menees et al., 2014). Another new contribution of our study is that it 
accounted for all adenomas including multiple adenomas within a colonic segment, and 
accounted for co-existing, multiple advanced adenoma characteristics. Most studies have 
not reported on co-existing multiple characteristics that qualify for an advanced adenoma 
designation. They identified one advanced characteristic among a patient’s adenomas and 
used a single feature for analysis (Lebwohl, Capiak, Neugut, & Kastrinos, 2012).  Unlike 
studies based on claims data or the Clinical Outcomes Research Initiative (CORI) 
database (Lieberman et al., 2008), our data has complete information on the number of 
polyps removed from each anatomic segment, enabling us to more accurately account for 
all adenomas found. We identified an additional 712 patients as increased risk patients 




number of polyp jars with a reported adenoma histology. Our study also did not limit 
analysis to the features of the largest adenoma, typical of other studies on colonoscopy 
findings (Lebwohl et al., 2012).  
  The reason for significant overuse in the post-guideline period among the 5-year 
surveillance group, 61.4% vs. 47.6% in the pre-period (not shown in tables) needs further 
study based on regional or multi-center samples. We could not explore the possible role 
of a family history of CRC due to lack of this data, a major study limitation. One study 
showed that screened patients with a family history of CRC are twice more likely to have 
completed surveillance than those without a family history (Schoen et al., 2010). 
Comorbidity is may be another consideration among both patients and providers in the 
surveillance decision. We could not study its role as data are not available. We also did 
not study provider factors in surveillance timing adherence as this is a single-center study. 
Provider factors are important due to varying levels of awareness, knowledge, and 
attitudes about practice guidelines across providers (Imperiale, 2011; Kruse et al., 2015; 
Saini et al., 2009).     
 Another study limitation is that the pathology reporting did not specify the number of 
polyps with differing histology within the same jar. The center transports multiple small 
polyps within a colonic segment with similar morphologic appearance in one polyp jar 
for histology, per standard practice consistent with insurer reimbursement criteria 
(Zauber, 2010). We assumed that reported adenoma histology applied to all polyps in the 
same jar. We also had fewer observation years to track surveillance use among post-
guideline patients (post-2006 period). This may have biased the observed completion rate; 




distinguish patient’s insurance status at surveillance colonoscopy, which may play a role 
in surveillance use.  
        In conclusion, patients with adenomas larger than 5 mm, and multiple advanced 
characteristics, not captured by the 2006 guideline criteria, were associated with 
premature surveillance. Further, surveillance overuse was most prevalent among the 5-
year recommended surveillance group. These factors need more exploration in multi-
center studies, and data with family history, comorbidities, and symptomatology 
information. Finally, our study also suggests a need to understand and reduce the barriers 


















Table 5.1 Study eligible patients with screening colonoscopy between Sep 4, 2001 and 
Feb 11, 2010 (n=16,805)   










Patient characteristics      
Gender
*
      
Male 7,629(45.4%) 1,993(26.1%) 5,636(73.9%) 
Female 9,096(54.1%) 1,993(21.9%) 7,103(78.1%) 
Missing 80(0.5%) 2(2.5%) 78(97.5%) 
Age at screening colonoscopy (years)
 *
      
40-49 2,746(16.3%) 476(17.3%) 2,270(82.7%) 
50-59 8,322(48.5%) 1,945(23.4%) 6,377(76.6%) 
60-74 5,737(34.1%) 1,567(27.3%) 4,170(72.7%) 
Race
*
      
White 7,433(44.2%) 1,678(22.6%) 5,755(77.4%) 
Black 8,721(51.9%) 2,178(25.0%) 6,543(75.0%) 
Other or unknown 651(3.9%) 132(20.3%) 519(79.7%) 
Insurance status at screening colonoscopy
*
      
Medicaid 522(3.1%) 113(21.7%) 409(78.4%) 
Medicare or Private  14,866(88.5%) 3,465(23.3%) 11,401(76.7%) 
Uninsured 1,417(8.4%) 410(28.9%) 1007(71.1%) 
Procedure-related characteristics      
Initial procedure year
*
      
Pre-2006 period (pre  
guideline) 9,461(56.3%) 3,306(34.9%) 6,155(65.1%) 
2006 and later 7,344(43.7%) 682(9.3%) 6,662(90.7%) 
No surveillance recommended 
(10-year rescreening only)  12,571(74.8%) 1,793(14.3%) 10,778(85.8%) 
Total surveillance-eligible
*
 4,234 2,195 2,039 
≤1-year surveillance 
**
 811(4.8%) 395(48.7%) 416(51.3%) 
3-year  surveillance 
**
 1,891(11.3%) 967(51.1%) 924(48.9%) 
5-year  surveillance 
**
 1,532(9.1%) 833(54.4%) 699(45.6%) 
Number of observation years per patient
#
 
(mean, SD)  5.33(2.55) 6.62(1.76) 4.93 (2.62) 
*
Chi-square test and ANOVA P<0.001.
**
Recommended surveillance interval as per 2006 guidelines; the 
interval is based on adenoma findings at screening colonoscopy;≤1 year for those with sessile adenomas are 
removed piecemeal, hyperplastic polyposis syndrome, or > 10 adenomas; 3 years for those with advanced 
adenoma status, 3-10 adenomas, ≥ 1 cm adenoma, villous features, or high-grade dysplasia; 5 years for 
those with 1 or 2 small tubular adenomas or any adenoma without advanced features.
#
Refers to number of 




Table 5.2 Surveillance-eligible study subjects classified by surveillance use relative to 












to due date)                        
(n=493) 
Not done 
 (by end of 
study period)                    
(n=2,039) 
Patient characteristics         
Gender         
Male 728(31.8%) 198(8.6%) 267(11.7%) 1,098(47.9%) 
Female 627(32.5%) 149(7.7%) 226(11.7%) 926(48.0%) 
Missing 0 0 0 15(100.00%) 
Age at screening 
colonoscopy (years)
*
         
40-49 131(27.2%) 41(8.5%) 49(10.2%) 260(54.1%) 
50-59 651(34.1%) 157(8.2%) 232(12.1%) 871(45.6%) 
60-74 573(31.1%) 149(8.1%) 212(11.5%) 908(49.3%) 
Race
*
         
White 623(30.3%) 166(8.1%) 228(11.1%) 1,038(50.5%) 
Black 691(34.2%) 170(8.4%) 248(12.3%) 910(45.1%) 
Other or unknown 41(25.6%) 11(6.9%) 17(10.6%) 91(56.9%) 
Insurance status at 
screening colonoscopy         
Medicaid 39(27.1%) 6(4.2%) 19(13.2%) 80(55.6%) 
Medicare or Private  1,191(32.5%) 301(8.2%) 431(11.8%) 1,743(47.6%) 
Uninsured 125(29.5%) 40(9.4%) 43(10.1%) 216(50.9%) 
Procedure-related 
characteristics         
Initial procedure year
*
         
Pre-2006 period (pre   
guideline) 970(32.7%) 255(8.6%) 410(13.8%) 1,334(44.9%) 




         
≤1-year surveillance 3(0.4%) 23(2.8%) 369(45.5%) 416(51.3%) 
*
























to due date)                        
(n=493) 
Not done 
 (by end of 
study period)                    
(n=2,039) 
3-year surveillance 589(31.2%) 281(14.9%) 97(5.1%) 924(48.9%) 
5-year surveillance 763(49.8%) 43(2.8%) 27(1.8%) 699(45.6%) 




SD) 6.06(2.02) 6.36(1.81) 6.65(1.55) 6.01(2.13) 
Polyp characteristics         
Adenoma status
*
         
Advanced adenoma/  
≥ 3 adenomas 592(24.15%) 304(12.4%) 333(13.6%) 1,222(49.9%) 
Non-advanced  
adenoma 763(42.79%) 43(2.4%) 160(9.0%) 817(45.8%) 
Location of the largest 
adenoma
*
         
Right 639(30.3%) 172(8.2%) 302(14.3%) 994(47.3%) 
Left 680(33.5%) 160(7.9%) 186(9.2%) 1,007(49.5%) 
Missing 36(38.3%) 15(16.0%) 5(5.3%) 38(40.4%) 




         
1-2 locations 1167 (34.1 %) 240 (7.0 %) 376 (11.0 %) 1640 (47.9%) 
3-4 locations 152 (21.2 %) 92 (12.8%) 112 (15.6 %) 361 (50.4%) 
Missing 36 (38.3%) 15 (16.0%) 5(5.3%) 38(40.4%) 
Size of largest 
adenoma
*
         
≤ 5mm 816(31.0%) 215(8.2%) 321(12.2%) 1,283(48.7%) 
5.1-9.9 mm 271(35.0%) 55(7.1%) 83(10.7%) 365(47.2%) 
≥10 mm 244(31.8%) 64(8.3%) 86(11.2%) 374(48.7%) 
Missing 24(42.1%) 13(22.8%) 3(5.3%) 17(29.8%) 
Number of adenomas
*
         
1-2 adenomas 925(41.1%) 89(4.0%) 199(8.9%) 1,036(46.1%) 
3+ adenomas 408(21.0%) 245(12.6%) 293(15.1%) 993(51.2%) 
Missing 22(47.8%) 13(28.3%) 1(2.2%) 10(21.7%) 
Has ≥ 2 adv. adenoma 
characteristics
*
         
No 1,230(31.3%) 326(8.3%) 460(11.7%) 1,917(48.7%) 
Yes  125(41.5%) 21(7.0%) 33(11.0%) 122(40.5%) 
*
Chi-square test P<0.05 for test of the difference between surveillance use and the respective characteristic 
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Table 5.3 Logistic regression model of the likelihood of completing the surveillance 
procedure among surveillance-eligible patients (n=4,234)
 
 
  OR (95%CI) 
Patient characteristics   
Gender: Female vs. male 0.98(0.86,1.11) 











Other or unknown 0.89(0.63,1.27) 
Insurance status (Ref: Uninsured)   
Medicaid 0.87(0.59,1.30) 
Medicare or Private 
**
 1.29(1.04,1.61) 
Procedure-related characteristics   
Initial procedure timing    
Post guideline
*
 (vs. pre-2006 period)
 **
 0.62(0.54,0.72) 
Recommended surveillance interval 
(Ref: ≤1-year surveillance)   




Polyp characteristics   
Anatomic location of the largest adenoma : Right (vs. Left) 1.08(0.95,1.22) 
Patient has ≥ 2 advanced adenoma characteristics
**
 1.64(1.28,2.11) 
Hosmer and Lemeshow Goodness-of-Fit statistic p=0.147 
*
Post guideline: screening colonoscopy done in 2006 or later.  
**














Table 5.4 Association of surveillance time interval (in years) with patient, procedure, and 













  Estimate Estimate Estimate Estimate 
Patient characteristics   
   Age(years)
 
(Ref: 40-49)   





 -0.21 0.03 
Procedure-related characteristics   
   Initial procedure timing: Post 









Recommended surveillance interval : 
3-year surveillance (vs. ≤1-year) 
0.11 - - - 
Recommended surveillance interval : 
5-year surveillance (vs. ≤1-year) 
0.19 - - - 
Polyp characteristics   
   Anatomic location of the largest 
adenoma : Right (vs. Left) 
0.06 -0.16 0.08 0.16
#
 
Size of largest adenoma :  








Size of largest adenoma :  
5.1-9.9mm (vs. ≤ 5 mm) 
- - - -0.65
#
 
Number of adenomas:  




Patient has ≥ 2 advanced adenoma 






 R square 0.185 0.165 0.186 0.103 
*
Gender, race, insurance status were not statistically significant (P>0.05), and exclude from the field 
models (data not shown).  
#
















Table 5.4a Association of surveillance time interval (in years) with patient, procedure, 
and polyp characteristics among the sub-group recommended to undergo surveillance at 5 







  Estimate SE Estimate SE 
Patient characteristics         
Gender : Female vs. male 0.07 0.08 0.06 0.08 
Age(years) (Ref: 40-49)         
50-59 0.18 0.13 0.24 0.13 
60-74 -0.02 0.14 0.03 0.13 
Race (Ref: White)         
Black -0.16
**
 0.08 -0.14 0.08 
Other or unknown 0.12 0.23 0.13 0.22 
Insurance status (Ref: Uninsured)         
Medicaid -0.14 0.25 0.10 0.24 
Medicare & Private  -0.03 0.13 0.20 0.13 
Procedure-related characteristics         
Initial procedure timing         





Polyp characteristics         
Anatomic location of the largest 




Size of largest adenoma :  


















Model 1 includes patient and colonoscopy characteristics, and Model 2 includes patient, 
colonoscopy, and adenoma characteristics. 
**















Table 5.5 Likelihood of overuse, delayed and not completed surveillance among 














 (by end of 
study period)  
OR (95%CI) 
Patient characteristics       
Gender: Female vs. male 1.08(0.83,1.39) 1.06(0.80,1.42) 1.10(0.86,1.40) 
Age(years) (Ref: 40-49)       
50-59 1.49(0.98,2.26) 1.23(0.77,1.98) 0.95(0.65,1.39) 
60-74 1.51(0.99,2.30) 1.12(0.70,1.81) 1.08(0.73,1.59) 
Race (Ref: White)       
Black 1.01(0.78,1.31) 1.04(0.78,1.39) 0.83(0.66,1.06) 
Other or unknown 0.85(0.41,1.75) 0.96(0.43,2.14) 0.99(0.51,1.94) 
Insurance status  
(Ref: Uninsured)       
Medicaid 1.85(0.70,4.90) 3.22(1.14,9.09) * 2.27(0.90,5.69) 
Medicare or Private  1.30(0.84,2.00) 1.52(0.93,2.50) 1.00(0.67,1.49) 
Procedure-related 
characteristics       
Initial procedure timing       
2006 and later  
(vs. Pre-2006 period) 1.73(1.30,2.31) * 0.50(0.35,0.70) * 1.86(1.42,2.43) * 
Recommended 
surveillance interval       
5-year surveillance  
(vs. ≤3-year surveillance) 14.39(10.03,20.64) * 0.31(0.18,0.53) * 4.41(3.11,6.25) * 
Polyp characteristics       
Anatomic location of the 
largest adenoma :  
Right (vs. Left) 0.86(0.67,1.11) 1.49(1.12,1.98) * 0.94(0.74,1.19) 
Size of largest adenoma :  
≥10 mm (vs. <10mm) 1.81(1.25,2.63) * 0.83(0.55,1.26) 1.28(0.91,1.80) 
Patient has ≥ 2 advanced 
adenoma characteristics 
(vs. 1) 2.26(1.30,3.93) * 1.15(0.60,2.20) 1.02(0.59,1.76) 
*







Table 5.6 Logistic regression model of the likelihood of non-completion surveillance (vs. 





Patient characteristics   
Gender   
Male  (ref) 
Female 1.03(0.90,1.16)  











Other or unknown 1.12(0.79,1.59) 
Insurance status at screening colonoscopy   
Medicaid 1.14(0.77,1.70) 
Medicare or Private  0.78(0.62,0.97) 
Uninsured (ref) 
Procedure-related characteristics   
Initial procedure timing    
Post guideline(vs. pre-2006 period)
*
 1.60(1.39,1.85) 
Recommended surveillance interval 
(Ref: ≤1-year surveillance)   




Polyp characteristics   
Anatomic location of the largest adenoma : Right (vs. Left) 0.93(0.82,1.05) 
Size of largest adenoma : ≥10 mm (vs. <10mm) 1.05(0.86,1.28) 
















Table 5.7 Logistic regression model of the likelihood of a 2nd procedure among those 






Patient characteristics   
Gender   
Male  (ref) 
Female
*
 0.83(0.74,0.92)  













Other or unknown 0.80(0.59,1.07) 
Insurance status at screening colonoscopy   
Medicaid 0.74(0.52,1.07) 
Medicare or Private  0.98(0.83,1.17) 
Uninsured (ref) 
Procedure-related characteristics   
Initial procedure timing 
     Pre-2006 period (ref) 
2006 and later  0.06(0.05,0.07) 
Polyp characteristics 







No polyp (ref) 
*
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